<SEC-DOCUMENT>0001171843-25-000493.txt : 20250129
<SEC-HEADER>0001171843-25-000493.hdr.sgml : 20250129
<ACCEPTANCE-DATETIME>20250129070016
ACCESSION NUMBER:		0001171843-25-000493
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250129
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250129
DATE AS OF CHANGE:		20250129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		25566643

	BUSINESS ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020
		BUSINESS PHONE:		972 (3) 914-8213

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_012925.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023"><head><title>Form 8-K</title></head><body style="font-size: 10pt"><div style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="Form8K" id="ixv-139">0000818686</ix:nonNumeric> <ix:nonNumeric format="ixt:booleanfalse" name="dei:AmendmentFlag" contextRef="Form8K" id="ixv-140">False</ix:nonNumeric></ix:hidden><ix:references> <link:schemaRef xlink:href="gnw-20190101.xsd" xlink:type="simple"/> </ix:references> <ix:resources> <xbrli:context id="Form8K"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-29</xbrli:startDate> <xbrli:endDate>2025-01-29</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:unit id="USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit> <xbrli:unit id="Shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit> <xbrli:unit id="USDPShares"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit> </ix:resources></ix:header></div><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt; font-weight: bold; text-align: center; margin-top: 6pt; margin-bottom: 0pt;">UNITED STATES</p><p style="font-size: 14pt; font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">SECURITIES AND EXCHANGE COMMISSION</p><p style="font-size: 14pt; font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 6pt;">Washington, D.C. 20549</p><p style="text-align: center;">_________________</p><p style="font-size: 14pt; font-weight: bold; text-align: center; margin-top: 6pt; margin-bottom: 6pt;">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="Form8K" id="ixv-160">8-K</ix:nonNumeric></p><p style="text-align: center;">_________________</p><p style="font-size: 12pt; font-weight: bold; text-align: center; margin-top: 6pt; margin-bottom: 6pt;">CURRENT REPORT</p><p style="font-size: 12pt; font-weight: bold; text-align: center; margin-top: 6pt; margin-bottom: 6pt;">Pursuant to Section 13 or 15(d)<br/>of the Securities Exchange Act of 1934</p><p style="font-size: 10pt; font-weight: bold; text-align: center; margin-top: 6pt; margin-bottom: 6pt;">Date of Report (Date of earliest event reported):&#160; <ix:nonNumeric format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" contextRef="Form8K" id="ixv-161">January 29, 2025</ix:nonNumeric></p><p style="text-align: center;">_______________________________</p><p style="font-size: 12pt; text-align: center; margin-top: 6pt; margin-bottom: 0; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="Form8K" id="ixv-162">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</ix:nonNumeric></p><p style="font-size: 10pt; text-align: center; margin-top: 0; margin-bottom: 6pt;">(Exact name of registrant as specified in its charter)</p><p style="text-align: center;">_______________________________</p><table style="width: 100%; margin-right: auto; margin-left: auto;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 33%; font-size: 10pt; font-weight: bold; text-align: center;"><ix:nonNumeric format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" contextRef="Form8K" id="ixv-163">Israel</ix:nonNumeric></td><td style="width: 34%; font-size: 10pt; text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="Form8K" id="ixv-164">001-16174</ix:nonNumeric></td><td style="width: 33%; font-size: 10pt; font-weight: bold; text-align: center;"><!--<ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="Form8K">00-0000000</ix:nonNumeric>-->Not Applicable</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt; text-align: center;">(State or other jurisdiction of Incorporation)</td><td style="font-size: 10pt; text-align: center;">(Commission File Number)</td><td style="font-size: 10pt; text-align: center;">(IRS Employer Identification Number)</td></tr></table><!-- Postal Address Country= --><p style="font-size: 10pt; text-align: center; margin-top: 12pt; margin-bottom: 0pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="Form8K" id="ixv-165">124 Dvora Hanevi&#8217;a Street</ix:nonNumeric></p><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="Form8K" id="ixv-166">Tel Aviv</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="Form8K" id="ixv-167">6944020</ix:nonNumeric>, <ix:nonNumeric format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" contextRef="Form8K" id="ixv-168">Israel</ix:nonNumeric></p><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 6pt;">(Address of Principal Executive Offices, including Zip Code)</p><!-- Phone Number --><p style="font-size: 10pt; font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">+<ix:nonNumeric name="dei:CityAreaCode" contextRef="Form8K" id="ixv-169">972</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="Form8K" id="ixv-170">3-914-8213</ix:nonNumeric></p><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 6pt;">(Registrant's Telephone Number, including Area Code)</p><!-- Former Name --><p style="font-size: 10pt; font-weight: bold; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">Not Applicable</p><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="text-align: center;">_______________________________</p><!-- Checkboxes --><p style="font-size: 10pt; text-align: left; text-indent: 0; margin-top: 6pt; margin-bottom: 6pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><table style="width: 100%; margin-top: 6pt; margin-bottom: 6pt; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 3%; text-align: center; vertical-align: middle;"><ix:nonNumeric format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" contextRef="Form8K" id="ixv-171">&#9744;</ix:nonNumeric></td><td style="width: 97%; text-align: left;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr><tr style="vertical-align: top;"><td style="width: 3%; text-align: center; vertical-align: middle;"><ix:nonNumeric format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" contextRef="Form8K" id="ixv-172">&#9744;</ix:nonNumeric></td><td style="width: 97%; text-align: left;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr><tr style="vertical-align: top;"><td style="width: 3%; text-align: center; vertical-align: middle;"><ix:nonNumeric format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" contextRef="Form8K" id="ixv-173">&#9744;</ix:nonNumeric></td><td style="width: 97%; text-align: left;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr><tr style="vertical-align: top;"><td style="width: 3%; text-align: center; vertical-align: middle;"><ix:nonNumeric format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" contextRef="Form8K" id="ixv-174">&#9744;</ix:nonNumeric></td><td style="width: 97%; text-align: left;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table><!-- Securities Table --><p style="font-size: 10pt; text-align: left; text-indent: 0; margin-top: 6pt; margin-bottom: 6pt;">Securities registered pursuant to Section 12(b) of the Act:</p><div><table border="0" cellspacing="0" cellpadding="0" style="width: 100%"><tr style="vertical-align: top"><td style="font-size: 10pt; text-align: center; margin-top: 6pt; margin-bottom: 6pt; width: 39%; border-bottom: Black 1pt solid">Title of each class</td><td style="font-size: 10pt; text-align: center; margin-top: 6pt; margin-bottom: 6pt; width: 23%; border-bottom: Black 1pt solid">Trading Symbol(s)</td><td style="font-size: 10pt; text-align: center; margin-top: 6pt; margin-bottom: 6pt; width: 38%; border-bottom: Black 1pt solid">Name of each exchange on which registered</td></tr><tr style="vertical-align: top"><td style="font-size: 10pt; text-align: center"><span><ix:nonNumeric contextRef="Form8K" name="dei:Security12bTitle" id="ixv-175">American Depositary Shares, each representing one Ordinary Share</ix:nonNumeric></span></td><td style="font-size: 10pt; text-align: center"><span><ix:nonNumeric contextRef="Form8K" name="dei:TradingSymbol" id="ixv-176">TEVA</ix:nonNumeric></span></td><td style="font-size: 10pt; text-align: center"><span><ix:nonNumeric contextRef="Form8K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-177">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><!-- Emerging Growth Company --><p style="font-size: 10pt; text-align: left; text-indent: 0; margin-top: 6pt; margin-bottom: 6pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-size: 10pt; text-align: right; text-indent: 0; margin-top: 6pt; margin-bottom: 6pt;">Emerging growth company <ix:nonNumeric format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" contextRef="Form8K" id="ixv-178">&#9744;</ix:nonNumeric></p><p style="font-size: 10pt; text-align: left; text-indent: 0; margin-top: 6pt; margin-bottom: 6pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 4pt solid;">&#160;</div><div style="page-break-before: always; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div><!-- 8-K Items --><div><div><div style="font-size: 10pt;"><strong>Item 2.02. Results of Operations and Financial Condition.</strong></div><div style="font-size: 10pt;"><p style="margin-left: 0in; margin-right: 0in;">On January 29, 2025, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.</p><p style="margin-left: 0in; margin-right: 0in;">The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p></div></div><div><div style="font-size: 10pt;"><strong>Item 9.01. Financial Statements and Exhibits.</strong></div><div style="font-size: 10pt;"><p style="margin-left: 0in; margin-right: 0in;">(d) Exhibits&#160;</p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="font-size: 10pt; font-weight: bold; text-decoration: underline;" valign="bottom">Exhibit No.</td><td style="font-size: 10pt; width: 20px;">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-decoration: underline;" valign="bottom">Description of Document</td></tr><tr><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt; width: 20px;">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr><td style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></td><td style="font-size: 10pt; width: 20px;">&#160;</td><td style="font-size: 10pt;"><a href="exh_991.htm">Teva Reports 2024 Full Year and Fourth Quarter Financial Results</a></td></tr><tr><td style="font-size: 10pt;">104</td><td style="font-size: 10pt; width: 20px;">&#160;</td><td style="font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr></table></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 4pt solid;">&#160;</div><div style="page-break-before: always; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div><!-- Signatures --><p style="font-size: 10pt; text-align: center; font-weight: bold;">SIGNATURES</p><p style="font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="width: 100%;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td>&#160;</td><td style="font-size: 10pt; font-weight: bold;" colspan="2">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</td></tr><tr style="vertical-align: top;"><td style="width: 49%;">&#160;</td><td style="width: 2%;">&#160;</td><td style="width: 49%;">&#160;</td></tr><tr style="vertical-align: top;"><td>&#160;</td><td>&#160;</td><td style="font-size: 10pt;"/></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">Date: January 29, 2025</td><td style="font-size: 10pt;">By:&#160;</td><td style="text-decoration: underline; font-size: 10pt;">/s/ Eli Kalif&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr><tr style="vertical-align: top;"><td>&#160;</td><td>&#160;</td><td style="font-size: 10pt;">Eli Kalif</td></tr><tr style="vertical-align: top;"><td>&#160;</td><td>&#160;</td><td style="font-size: 10pt;">Executive Vice President, Chief Financial Officer</td></tr><tr style="vertical-align: top;"><td>&#160;</td><td>&#160;</td><td style="font-size: 10pt;"/></tr></table><!-- Exhibit Index --><div></div><!-- +972- 3-914-8213 Form 8-KJanuary 29, 2025 --><p>&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><strong>Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth</strong></p><p style="text-align: center;" ></p><p>
  <ul type="disc"><li>2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;</li><li>AUSTEDO<sup>&#174;</sup> - exceeding $1.6 billion in revenues, surpassing 2024 outlook;</li><li>AJOVY<sup>&#174;</sup> - global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023;</li><li>UZEDY<sup>&#174;</sup> revenues of $117 million in 2024 surpassing $100M outlook;</li><li>Generics business continues to grow across all segments, with increases of 15% in the U.S., 6% in Europe and 15% in International Markets, all in local currency terms compared to 2023;</li><li>First-to-market launches including first generic version of Sandostatin<sup>&#174; </sup>LAR Depot and liraglutide injection 1.8mg (an authorized generic of Victoza<sup>&#174;</sup>); On January 2025, Teva entered into a license and supply agreement, for a proposed generic GLP1 in the U.S., Europe and additional countries;</li><li>Biosimilar pipeline is expanding, and now includes 18 assets, including SELARSDI<sup>TM</sup>, which is expected to launch in the U.S. in the first quarter of 2025; and our first internally developed biosimilar to Prolia<sup>&#174;</sup> (denosumab), which is under regulatory review in the U.S. and in Europe;</li><li>Duvakitug (Anti-TL1A) positive Phase 2B results announced and initiation of Phase 3 program is expected in 2025; olanzapine LAI achieved Phase 3 targeted injections without PDSS (post-injection delirium/sedation syndrome), and full safety presentation is expected in the second quarter of 2025.</li></ul>   <ul><li><strong>Q4 2024 and FY 2024 highlights</strong>:</li></ul>  <table align="center" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:75%; width:75%; min-width:75%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong><u>Q4 </u></strong><strong><u>2024</u></strong></td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong><u>FY </u></strong><strong><u>2024</u></strong></td></tr><tr><td style="vertical-align: bottom ; ">Revenues</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$4.2 billion</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$16.5 billion</td></tr><tr><td style="vertical-align: bottom ; ">GAAP loss per share</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$0.19</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;$1.45</td></tr><tr><td style="vertical-align: bottom ; ">Non-GAAP diluted EPS</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$0.71</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$2.49</td></tr><tr><td style="vertical-align: bottom ; ">Cash flow generated from operating activities</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$575 million</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$1,247 million</td></tr><tr><td style="vertical-align: bottom ; ">Free cash flow</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$790 million</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$2,068 million</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr></table>  <p><strong>2025 Outlook * </strong></p>   <ul type="circle"><li>Revenues of $16.8 - $17.4 billion</li><li>Non-GAAP operating income of $4.1-$4.6 billion</li><li>Adjusted EBITDA of $4.5 - $5.0 billion</li><li>Non-GAAP diluted EPS of $2.35 - $2.65</li><li>Free cash flow of $1.6 - $1.9 billion</li></ul>   <p>*&#160; 2025 outlook assumes a full year contribution from Teva api and our business venture in Japan and excludes the expected income from potential milestone payments from Sanofi in connection with the Phase 3 initiation of duvakitug.</p>   <p align="justify">TEL AVIV, Israel, Jan.  29, 2025  (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2024.</p>   <p align="justify">Mr. Richard Francis, Teva's President and CEO, said: "2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products. Focusing on rigorous execution of our Pivot to Growth strategy throughout the year, we continued to achieve important milestones in each of its four pillars, including surpassing the outlook for our key innovative products, growing our generics business across all segments, and accelerating our early-stage innovative pipeline, including the positive Phase 2b results for our duvakitug (anti-Tl1A) asset. These results pave the way for pivotal trials in Crohn&#8217;s disease and ulcerative colitis, as well as, potentially, other Immunological and fibrotic indications beyond, in collaboration with our partner, Sanofi."</p>   <p align="justify">Mr. Francis continued, "In 2025, we anticipate further progress in our key innovative growth drivers, while also executing on our complex generics and biosimilars business, supported by new product launches. We are also excited to advance to Phase 3 trials for our duvakitug (anti-TL1A) asset."</p>   <p align="justify"><strong>Pivot to Growth Strategy</strong></p>   <p align="justify">In 2024, we continued to execute on the four key pillars of our &#8220;Pivot to Growth&#8221; strategy, which we announced in May 2023.&#160;</p>   <ul type="disc"><li>On the first pillar, <strong>delivering on our growth engines,</strong> we continued to show strong performance of our key innovative products, mainly AUSTEDO, AJOVY, and UZEDY, as well as on our late-stage pipeline of biosimilars, with the launches of SIMLANDI<sup>&#174;</sup> (adalimumab-ryvk) injection and the expected launch of SELARSDI (ustekinumab-aekn) injection, and the progress we made on our proposed biosimilars to Prolia<sup>&#174;</sup>(denosumab), Simponi<em><sup>&#174;</sup></em> and Simponi Aria<em><sup>&#174;</sup></em> (golimumab), which were submitted for regulatory review in the U.S. and the EU;&#160;</li><li>On the second pillar, <strong>stepping up innovation </strong>through delivering on our late-stage innovative pipeline, we have been accelerating the development of certain key pipeline assets, including the recent positive Phase 2b results for duvakitug (anti-TL1A), and expect a number of milestones and data points for olanzapine LAI, and DARI (dual-action asthma rescue inhaler, ICS/SABA) in the near future;&#160;</li><li>On the third pillar, <strong>sustaining our generics powerhouse </strong>with a global commercial footprint, focused portfolio, pipeline and manufacturing footprint, we continued to optimize our generics business and build a strong pipeline of biosimilars, with several successful launches of high-value complex generics in 2024; and</li><li>Lastly, on our fourth pillar, <strong>focusing our business </strong>by optimizing our portfolio and global manufacturing footprint. This will enable strategic capital deployment, to accelerate our growth engines, and reorganize certain of our business units to a more optimal structure. We continued our efforts on capital allocation and disciplined cost management by focusing on debt repayment, and optimizing our working capital management.</li><li>Teva continues to progress with the sale of its active-pharmaceutical ingredient (API) business and is engaged with prospective purchasers. The timing and structure of the planned transaction are subject to ongoing consideration and the consummation of the sale remains contingent on reaching a definitive agreement, subject to approval by Teva's Board of Directors. On December 31, 2024, Teva classified its API business (including its R&amp;D, manufacturing and commercial activities) as held for sale.</li></ul>   <p align="justify"><strong><u>2024 Annual Consolidated Results</u></strong></p>   <p align="justify"><strong>Revenues</strong> in 2024 were $16,544 million, an increase of 4%, in U.S. dollars, or 6% in local currency terms, compared to 2023. This increase was mainly due to higher revenues from generic products in all our segments, including from lenalidomide capsules (the generic version of Revlimid<sup>&#174;</sup>) in our U.S. segment, from our innovative products AUSTEDO, UZEDY and AJOVY, as well as the sale of certain product rights, partially offset by an upfront payment of $500 million received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, and lower revenues from certain innovative products, primarily COPAXONE and BENDEKA and TREANDA.</p>   <p align="justify"><strong>Exchange rate</strong> movements during 2024, net of hedging effects, negatively impacted overall revenues by $257 million, operating income by $103 million and non-GAAP operating income by $104 million, each as compared to 2023.</p>   <p align="justify"><strong>Gross </strong><strong>profit</strong> in 2024 was $8,064 million, an increase of 5% compared to 2023. <strong>Gross profit margin</strong> was 48.7% in 2024, compared to 48.2% in 2023. This increase in gross profit margin was mainly due to a favorable mix of products, primarily driven by higher revenues from AUSTEDO and lenalidomide capsules (the generic version of Revlimid<sup>&#174;</sup>), and the sale of certain product rights, partially offset by an upfront payment received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset. <strong>Non-</strong><strong>GAAP</strong> <strong>gross profit </strong>was $8,814 million in 2024, an increase of 4% compared to 2023. <strong>Non-GAAP</strong> <strong>gross profit margin</strong> was 53.3% in 2024, compared to 53.5% in 2023. This decrease was mainly due to an upfront payment received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, and lower revenues from COPAXONE, partially offset by higher revenues from AUSTEDO, the sale of certain product rights, as well as higher revenues from lenalidomide capsules (the generic version of Revlimid<sup>&#174;</sup>).</p>   <p align="justify"><strong>Research and Development (R&amp;D)</strong> <strong>expenses</strong>, <strong>net</strong> in 2024 were $998 million, an increase of 5% compared to $953 million in 2023, as we continue to execute on our Pivot to Growth strategy. Our higher R&amp;D expenses, net in 2024, compared to 2023, were mainly due to an increase in immunology and in immuno-oncology, our late-stage innovative pipeline in neuroscience (mainly neuropsychiatry), and our biosimilars pipeline, partially offset by a decline in various generics projects. Our R&amp;D expenses, net in 2024 were also impacted positively by reimbursements from our strategic partnerships entered in 2023 and 2024.</p>   <p align="justify"><strong>Selling and Marketing (S&amp;M)</strong> <strong>expenses</strong> in 2024 were $2,541 million, an increase of 9% compared to 2023. This increase was mainly to support revenue growth.</p>   <p align="justify"><strong>General and Administrative (G&amp;A) expenses</strong> in 2024 were $1,161 million, flat compared to 2023.</p>   <p align="justify"><strong>Other income</strong> in 2024 was $14 million, compared to $49 million in 2023. Other income in 2023 included a capital gain from the sale of assets in our International Markets segment.</p>   <p align="justify"><strong>Operating loss</strong> was $303 million in 2024, compared to operating income of $433 million in 2023. Operating loss as a percentage of revenues was 1.8% in 2024, compared to operating income as a percentage of revenues of 2.7% in 2023. This decrease was mainly due to higher goodwill and other assets impairment charges as well as increased S&amp;M expenses, partially offset by higher gross profit and lower legal settlements and loss contingencies.<strong> Non-GAAP operating income</strong> was $4,329 million in 2024, representing a non-GAAP operating margin of 26.2% compared to $4,361 million, representing a non-GAAP operating margin of 27.5% of revenues in 2023. The decrease in non-GAAP operating margin was mainly due to higher operating expenses as a percentage of revenues, as well as lower non-GAAP gross profit margin, as discussed above.</p>   <p align="justify">In 2024, <strong>financial expenses, net</strong> were $981 million, compared to $1,057 million in 2023. Financial expenses in 2024 and 2023 were mainly comprised of net-interest expenses of $915 million, and $961 million, respectively.</p>   <p align="justify">In 2024, we recognized a <strong>tax </strong><strong>expense</strong> of $676 million on a pre-tax loss of $1,284 million. In 2023, we recognized a tax benefit of $7 million, on a pre-tax loss of $624 million. Our effective tax rate is the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to non-Israeli subsidiaries that have tax rates different than Teva&#8217;s average tax rate, a settlement agreement with the Israeli Tax Authorities, impairment charges with no corresponding tax effects, net deferred tax benefits from intellectual property related integration plans, an adjustment to the Company&#8217;s corporate tax rate in Israel on losses related to non-qualified tax incentive activities in Israel, adjustments to valuation allowances on deferred tax assets, adjustments to uncertain tax positions and interest expense disallowances.</p>   <p align="justify"><strong>Non-GAAP</strong> <strong>tax rate</strong> for 2024 was 15.3%, compared to 13.0% in 2023. Our non-GAAP tax rate of 2024 was the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to non-Israeli subsidiaries that have tax rates different than Teva&#8217;s average tax rate, net deferred tax benefits from intellectual property-related integration plans, adjustments to valuation allowances on deferred tax assets, adjustments to uncertain tax positions and interest expense disallowances.</p>   <p align="justify"><strong>Net loss</strong> attributable to Teva and <strong>loss per share</strong> in 2024 were $1,639 million and $1.45, respectively, compared to net loss attributable to Teva of $559 million and loss per share of $0.50, respectively, in 2023. The change in net loss attributable to Teva was mainly due to higher income taxes, as well as higher operating loss in 2024, partially offset by higher net loss attributable to non-controlling interests. <strong>Non-GAAP net income</strong> attributable to Teva and <strong>non-GAAP diluted earnings per share </strong>in 2024 were $2,860 million and $2.49, respectively, compared to $2,898 million and $2.56 in 2023.</p>   <p align="justify"><strong>Adjusted</strong><strong> EBITDA</strong> was $4,781 million in 2024, compared to $4,818 million in 2023.</p>   <p align="justify">As of December 31, 2024 and 2023, the <strong>fully diluted share count for purposes of calculating our market capitalization</strong> was approximately 1,174 million and 1,157 million, respectively.</p>   <p align="justify"><strong>Non-GAAP information</strong>: net non-GAAP adjustments in 2024 were $4,499 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the year were adjusted to exclude the following items:</p>   <ul type="disc"><li>Amortization of purchased intangible assets totaling $588 million, of which $543 million is included in cost of goods sold and the remaining $45 million in S&amp;M expenses;</li><li>Legal settlements and loss contingencies of $761 million mainly related to a provision of $357 million recorded in connection with a decision by the European Commission in its antitrust investigation into COPAXONE, and $278 million related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore);</li><li>Goodwill impairment charges of $1,280 million related to the Teva API reporting unit;</li><li>Impairment of long-lived assets of $1,275 million mainly related to the classification of our business venture in Japan and our API business as held for sale;</li><li>Restructuring expenses of $74 million;</li><li>Equity compensation expenses of $123 million;</li><li>Contingent consideration expenses of $303 million;</li><li>Gain on sale of business of $15 million;</li><li>Accelerated depreciation of $13 million;</li><li>Financial expenses of $49 million;</li><li>Items attributable to non-controlling interests of $339 million;</li><li>Other non-GAAP items of $229 million; and</li><li>Corresponding tax effects and unusual tax items expenses of $157 million.</li></ul>   <p align="justify">We believe that excluding such items facilitates investors&#8217; understanding of our business including underlying performance trends, thereby improving the comparability of our business performance results between reporting periods.</p>   <p align="justify">For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under &#8220;Non-GAAP Financial Measures.&#8221; Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.</p>   <p align="justify"><strong>Cash flow generated from operating activities</strong> in 2024 was $1,247 million, compared to $1,368 million in 2023. The decrease in 2024 resulted mainly from an upfront payment received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, a negative impact from accounts payables, the classification of payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<sup>&#174;</sup>) as cash flow used in operating activities, and higher tax payments, partially offset by higher profits from AUSTEDO and from the sale of certain product rights, lower inventory levels, and a positive impact from accounts receivables.</p>   <p align="justify">During 2024, we generated <strong>free cash flow</strong> of $2,068 million, which we define as comprising $1,247 million in cash flow generated from operating activities, $1,291 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $43 million proceeds from divestitures of businesses and other assets, partially offset by $498 million in cash used for capital investments and $15 million in cash used for acquisition of businesses, net of cash acquired.</p>   <p align="justify">During 2023, we generated <strong>free cash flow</strong> of $2,387 million, which we define as comprising $1,368 million in cash flow generated from operating activities, $1,477 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $68 million proceeds from divestitures of businesses and other assets, partially offset by $526 million in cash used for capital investments. The decrease in 2024 resulted mainly from lower cash flow generated from operating activities.</p>   <p align="justify">As of December 31, 2024, our <strong>debt</strong> was $17,783 million, compared to $19,833 million as of December 31, 2023. This decrease was mainly due to the repayment at maturity of $1,641 million of our senior notes and $429 million of exchange rate fluctuations. The portion of total debt classified as short-term as of December 31, 2024 was 10%, compared to 8% as of December 31, 2023.</p>   <p align="justify">Our average debt maturity was approximately 5.5 years as of December 31, 2024, compared to 6.0 years as of December 31, 2023.</p>   <p align="justify"><strong>Fourth </strong><strong>Quarter 2024 Consolidated Results</strong></p>   <p align="justify"><strong>Revenues</strong> in fourth quarter of 2024 were $4,229 million, a decrease of 5% in both U.S. dollars and in local currency terms, compared to the fourth quarter of 2023. This decrease was mainly due to an upfront payment of $500 million received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, partially offset by higher revenues from our innovative products AUSTEDO, UZEDY and AJOVY, from generic products in all our segments and from the sale of certain product rights.&#160;</p>   <p align="justify"><strong>Exchange rate</strong> movements during the fourth quarter of 2024, net of hedging effects, negatively impacted overall revenues by $8 million, compared to the fourth quarter of 2023.</p>   <p align="justify"><strong>Gross profit</strong> in the fourth quarter of 2024 was $2,120 million, a decrease of 12% compared to $2,416 million in the fourth quarter of 2023. <strong>Gross profit margin</strong> was 50.1% in the fourth quarter of 2024, compared to 54.2% in the fourth quarter of 2023. <strong>Non-GAAP gross profit</strong> was $2,319 million in the fourth quarter of 2024, a decrease of 11%, compared to $2,592 million in the fourth quarter of 2023. <strong>Non-GAAP gross profit margin</strong> was 54.8% in the fourth quarter of 2024, compared to 58.2% in the fourth quarter of 2023. The decrease in both gross profit margin and non-GAAP gross profit margin was mainly due to the upfront payment received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, as well as lower revenues from COPAXONE, partially offset by higher revenues from AUSTEDO, as well as the sale of certain product rights.</p>   <p align="justify"><strong>Research and Development (R&amp;D)</strong> <strong>expenses, net</strong> in the fourth quarter of 2024 were $248 million, an increase of 9% compared to $227 million in the fourth quarter of 2023, as we continue to execute on our Pivot to Growth strategy. Our higher R&amp;D expenses, net in the fourth quarter of 2024 compared to the fourth quarter of 2023, were mainly due to an increase in our late-stage innovative pipeline in neuroscience (mainly neuropsychiatry), in immunology, and in immuno-oncology.</p>   <p align="justify"><strong>Selling and Marketing (S&amp;M) expenses</strong> in the fourth quarter of 2024 were $650 million, an increase of 7% compared to the fourth quarter of 2023. This increase was mainly to support revenue growth in our innovative portfolio, primarily AUSTEDO, generic products and AJOVY.</p>   <p align="justify"><strong>General and Administrative (G&amp;A) expenses</strong> in the fourth quarter of 2024 were $302 million, an increase of 4% compared to the fourth quarter of 2023.</p>   <p align="justify"><strong>Other loss (income)</strong> in the fourth quarter of 2024 was a loss of $8 million, compared to an income of $6 million in the fourth quarter of 2023.</p>   <p align="justify"><strong>Operating loss</strong> in the fourth quarter of 2024 was $29 million, compared to an operating income of $755 million in the fourth quarter of 2023. Operating loss as a percentage of revenues was 0.7% in the fourth quarter of 2024, compared to an operating income as a percentage of revenues of 17% in the fourth quarter of 2023. <strong>Non-GAAP operating income</strong> in the fourth quarter of 2024 was $1,168 million representing a non-GAAP operating margin of 27.6%, compared to non-GAAP operating income of $1,546 million representing a non-GAAP operating margin of 34.7% in the fourth quarter of 2023. The decrease in non-GAAP operating margin in the fourth quarter of 2024 was mainly due to an increase in operating expenses as a percentage of revenues, as well as due to lower non-GAAP gross profit margin, as discussed above.</p>   <p align="justify">Exchange rate movements during the fourth quarter of 2024, net of hedging effects, positively impacted our operating income and non-GAAP operating income by $21 million and $20 million, respectively, compared to the fourth quarter of 2023.</p>   <p align="justify"><strong>Financial expenses, net</strong> in the fourth quarter of 2024 were $218 million, mainly comprised of net-interest expenses of $224 million. In the fourth quarter of 2023, financial expenses, net were $249 million, mainly comprised of net-interest expenses of $238 million.</p>   <p align="justify">In the fourth quarter of 2024, we recognized a <strong>tax expense</strong> of $29 million, on a pre-tax loss of $247 million. In the fourth quarter of 2023, we recognized a tax expense of $43 million, on a pre-tax income of $507 million. Our effective tax rate for the fourth quarter of 2024 was the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to non-Israeli subsidiaries that have tax rates different than Teva&#8217;s average tax rate, impairment charges with no corresponding tax effects, net deferred tax benefits from intellectual property related integration plans, adjustments to valuation allowances on deferred tax assets, adjustments to uncertain tax positions and interest expense disallowances.</p>   <p align="justify"><strong>Non-GAAP tax rate</strong> in the fourth quarter of 2024 was 14.8%, compared to 13.1% in the fourth quarter of 2023. Our non-GAAP tax rate in the fourth quarter of 2024 was the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to non-Israeli subsidiaries that have tax rates different than Teva&#8217;s average tax rate, net deferred tax benefits from intellectual property related integration plans, adjustments to valuation allowances on deferred tax assets, adjustments to uncertain tax positions and interest expense disallowances.</p>   <p align="justify"><strong>Net loss </strong>attributable to Teva and <strong>loss per share</strong> in the fourth quarter of 2024 were $217 million and $0.19, respectively, compared to net income attributable to Teva and earning per share $461 million and $0.41, respectively, in the fourth quarter of 2023. The higher net loss in the fourth quarter of 2024 was mainly due to lower operating income, as discussed above.</p>   <p align="justify"><strong>Non-GAAP net income</strong> attributable to Teva and <strong>non-GAAP diluted earnings per share</strong> in the fourth quarter of 2024 were $816 million and $0.71, respectively, compared to $1,135 million and $1.00, respectively, in the fourth quarter of 2023.</p>   <p align="justify"><strong>Adjusted EBITDA</strong> was $1,282 million in the fourth quarter of 2024, a decrease of 23%, compared to $1,660 million in the fourth quarter of 2023.</p>   <p align="justify"><strong>Non-GAAP information</strong>: net non-GAAP adjustments in the fourth quarter of 2024 were $1,033 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the fourth quarter of 2024 were adjusted to exclude the following items:</p>   <ul type="disc"><li>Amortization of purchased intangible assets of $144 million, of which $134 million is included in cost of sales and the remaining $10 million in S&amp;M expenses;</li><li>An adjustment to impairment of long-lived assets of $517 million;</li><li>Goodwill impairment charge of $280 million;</li><li>Legal settlements and loss contingencies of $123 million;</li><li>An adjustment to contingent consideration of $2 million;</li><li>Equity compensation expenses of $34 million;</li><li>Restructuring expenses of $22 million;</li><li>Loss on sale of business of $6 million;</li><li>Accelerated depreciation of $5 million;</li><li>Financial expenses of $13 million;</li><li>Other non-GAAP items of 67 million;</li><li>Items attributable to non-controlling interests of $63 million; and</li><li>Corresponding tax effects and unusual tax items of $114 million. &#160;</li></ul>   <p align="justify">We believe that excluding such items facilitates investors&#8217; understanding of our business including underlying performance trends, thereby improving the comparability of our business performance results between reporting periods.</p>   <p align="justify">For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under &#8220;Non-GAAP Financial Measures.&#8221; Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.</p>   <p align="justify"><strong>Cash flow generated from operating activities</strong> during the fourth quarter of 2024 was $575 million, compared to $1,184 million of cash flow generated from operating activities in the fourth quarter of 2023. The lower cash flow generated from operating activities in the fourth quarter of 2024 resulted mainly from changes in working capital items, including a&#160;negative impact of accounts payables, the classification of payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<sup>&#174;</sup>) as cash flow used in operating activities, an upfront payment received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, partially offset by lower legal payments during the fourth quarter of 2024, mainly in connection with our opioids litigation.</p>   <p align="justify">During the fourth quarter of 2024, we generated <strong>free cash flow</strong> of $790 million, which we define as comprising $575 million in cash flow generated from operating activities, $340 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $4 million in divestitures of businesses and other assets, partially offset by $129 million in cash used for capital investment. During the fourth quarter of 2023, we generated free cash flow of $1,486 million, which we define as comprising $1,184 million in cash flow generated from operating activities, $421 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program), partially offset by $120 million in cash used for capital investment. This decrease resulted mainly from lower cash flow generated from operating activities.</p>   <p align="justify"><strong>Segment Results for the Fourth Quarter of 2024</strong></p>   <p align="justify"><strong>United States Segment</strong></p>   <p align="justify">As part of a recent shift in executive management responsibilities and in line with our Pivot to Growth strategy, commencing January 1, 2024, Canada is reported as part of our International Markets segment. Prior period amounts were recast to reflect this change.</p>   <p align="justify">The following table presents revenues, expenses and profit for our United States segment for the three months ended December 31, 2024 and 2023:</p>  <table align="left" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:50%; width:50%; min-width:50%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="6" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; "><strong>Three months ended December 31,</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td></tr><tr><td class="hugin">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions / % of Segment Revenues)</strong><strong><br ></strong></td></tr><tr><td style="vertical-align: bottom ; ">Revenues</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1,975</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">100%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2,266</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">100%</td></tr><tr><td style="vertical-align: bottom ; ">Cost of sales</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">877</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">44.4%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">822</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">36.3%</td></tr><tr><td style="vertical-align: bottom ; ">Gross profit</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1,097</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">55.6%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1,444</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">63.7%</td></tr><tr><td style="vertical-align: bottom ; ">R&amp;D expenses</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">158</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">8.0%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">144</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">6.3%</td></tr><tr><td style="vertical-align: bottom ; ">S&amp;M expenses</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">260</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">13.2%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">238</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">10.5%</td></tr><tr><td style="vertical-align: bottom ; ">G&amp;A expenses</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">109</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">5.5%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">90</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">4.0%</td></tr><tr><td style="vertical-align: bottom ; ">Other loss (income)</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#167;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(1)</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#167;</td></tr><tr><td style="vertical-align: bottom ; ">Segment profit*</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">569</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">28.8%</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">974</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">43.0%</td></tr><tr><td colspan="7" style="vertical-align: bottom ; ">* Segment profit does not include amortization and certain other items.<br >&#167; Represents an amount less than 0.5%.</td></tr><tr><td colspan="7" style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p align="justify"><strong>Revenues </strong>from our United States segment in the fourth quarter of 2024 were $1,975 million, a decrease of $291 million, or 13%, compared to the fourth quarter of 2023. This decrease was mainly due to an upfront payment received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, partially offset by higher revenues from our innovative products AUSTEDO, and UZEDY, as well as the revenues from the sale of certain product rights.</p>   <p align="justify"><strong><em>Revenues by Major Products and Activities</em></strong></p>   <p align="justify">The following table presents revenues for our United States segment by major products and activities for the three months ended December 31, 2024 and 2023:</p>  <table align="left" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three months ended</strong><br ><strong>December 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Percentage</strong><br ><strong>Change</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024-2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td></tr><tr><td style="max-width:59%; width:59%; min-width:59%;;vertical-align: bottom ; "><strong>&#160;</strong></td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;border-top: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;border-top: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;border-top: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;border-top: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Generic products (including biosimilars)</td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="vertical-align: bottom ; ">$</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">674</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">667</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1%</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY</td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">63</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">57</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">11%</td></tr><tr><td style="vertical-align: bottom ; ">AUSTEDO</td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">518</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">408</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">27%</td></tr><tr><td style="vertical-align: bottom ; ">BENDEKA and TREANDA</td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">41</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">52</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(21%)</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE</td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">63</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">72</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(13%)</td></tr><tr><td style="vertical-align: bottom ; ">UZEDY</td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">43</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">9</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">N/A</td></tr><tr><td style="vertical-align: bottom ; ">Anda</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">402</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">394</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2%</td></tr><tr><td style="vertical-align: bottom ; ">Other*</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">171</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">607</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(72%)</td></tr><tr><td style="vertical-align: bottom ; ">Total</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1,975</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2,266</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(13%)</td></tr><tr><td colspan="9" style="text-align: justify ;  vertical-align: middle; vertical-align: top ; ">*Other revenues in the fourth quarter of 2024 include the sale of certain product rights. Other revenues in the fourth quarter of 2023 were mainly comprised of a $500 million upfront payment received in connection with the collaboration on our duvakitug (anti-TL1A) asset.</td></tr><tr><td colspan="9" style="text-align: justify ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr></table>  <p align="justify"><strong>Generic products</strong> (including biosimilars) revenues in our United States segment in the fourth quarter of 2024 were $674 million, an increase of 1% compared to the fourth quarter of 2023, the majorityof which is driven by the launch of liraglutide injection 1.8mg (an authorized generic of Victoza<sup>&#174;</sup>) and higher revenues from Truxima<sup>&#174;</sup> (the biosimilar to Rituxan<sup>&#174;</sup>), partially offset by lower revenues from lenalidomide capsules (the generic version of Revlimid<sup>&#174;</sup>) and albuterol sulfate inhalation aerosol (our ProAir<sup>&#174;</sup> authorized generic).</p>   <p align="justify">Among the most significant generic products we sold in the United States in the fourth quarter of 2024 were Truxima<sup>&#174;</sup> (the biosimilar to Rituxan<sup>&#174;</sup>), epinephrine injectable solution (the generic equivalent of EpiPen<sup>&#174;</sup> and EpiPen Jr<sup>&#174;</sup>), and liraglutide 1.8 mg injection (an authorized generic of Victoza<sup>&#174;</sup>).</p>   <p align="justify">In the fourth quarter of 2024, according to IQVIA data, our total prescriptions were approximately 68 million, representing 6.9% of total U.S. generic prescriptions.</p>   <p align="justify">On February 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira<sup>&#174;</sup>, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn&#8217;s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. On May 21, 2024, Alvotech and Teva announced the availability of SIMLANDI in the U.S.</p>   <p align="justify">On April 16, 2024, Alvotech and Teva announced that the FDA has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara<sup>&#174;</sup>, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients six years and older. SELARSDI is expected to launch in the U.S. in the first quarter of 2025.</p>   <p align="justify">On June 24, 2024, Teva announced the launch of liraglutide injection 1.8mg (an authorized generic of Victoza<sup>&#174;</sup>) in the United States. Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.</p>   <p align="justify">In July 2024, Teva launched paclitaxel protein-bound particles for injectable suspension (albumin-bound) (a therapeutically equivalent product to Abraxane<sup>&#174;</sup>) in the United States for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease, the treatment of locally advanced or metastatic non-small cell lung cancer, and the treatment of patients with metastatic adenocarcinoma of the pancreas.</p>   <p align="justify">On October 1, 2024, Teva launched octreotide acetate for injectable suspension, the first generic version of Sandostatin<sup>&#174;</sup> LAR Depot. Octreotide acetate for injectable suspension is indicated for the treatment of acromegaly and severe diarrhea associated with carcinoid syndrome, and is available to patients in the U.S.</p>   <p align="justify"><strong>AJOVY </strong>revenues in our United States segment in the fourth quarter of 2024 were $63 million, an increase of 11% compared to the fourth quarter of 2023, mainly due to growth in volume, partially offset by unfavorable net pricing. In the fourth quarter of 2024, AJOVY&#8217;s exit market share in the United States in terms of total number of prescriptions was 29.6% compared to 25.7% in the fourth quarter of 2023.</p>   <p align="justify"><strong>AUSTEDO</strong> revenues in our United States segment in the fourth quarter of 2024 increased by 27%, to $518 million, compared to $408 million in the fourth quarter of 2023, mainly due to growth in volume, as well as expanded access for patients.</p>   <p align="justify"><strong>AUSTEDO XR</strong> (deutetrabenazine) extended-release tablets were approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023. In May 2024, the FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg. In July 2024, the FDA approved the 18 mg dosage for AUSTEDO XR, making it a one pill, once-daily option for all available doses. AUSTEDO XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington&#8217;s disease, which is additional to the currently marketed twice-daily AUSTEDO. AUSTEDO XR is protected by 11 Orange Book patents expiring between 2031 and 2041.&#160;</p>   <p align="justify"><strong>UZEDY</strong> (risperidone) extended-release injectable suspension revenues in our United States segment in the fourth quarter of 2024 were $43 million. UZEDY was approved by the FDA on April 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023. UZEDY is a subcutaneous, long-acting formulation of risperidone that controls the steady release of risperidone. UZEDY is protected by four Orange Book patents expiring between 2027 and 2040. UZEDY is protected by regulatory exclusivity until April 28, 2026. We are moving forward with plans to launch UZEDY in other countries worldwide. UZEDY faces competition from multiple other products.</p>   <p align="justify"><strong>BENDEKA</strong> and <strong>TREANDA</strong> (bendamustine) combined revenues in our United States segment in the fourth quarter of 2024 were $41 million, a decrease of 21% compared to the fourth quarter of 2023, mainly due to competition from alternative therapies, as well as the entry of generic bendamustine products into the market. The orphan drug exclusivity that had attached to bendamustine products expired in December 2022.</p>   <p align="justify"><strong>COPAXONE</strong> revenues in our United States segment in the fourth quarter of 2024 were $63 million, a decrease of 13% compared to the fourth quarter of 2023, mainly due to market share erosion and competition, partially offset by a reduction in sales allowance.</p>   <p align="justify"><strong>Anda</strong> revenues from third-party products in our United States segment in the fourth quarter of 2024 increased by 2% to $402 million, compared to $394 million in the fourth quarter of 2023, mainly due to higher volume. Anda, our distribution business in the United States, distributes generic, biosimilars and innovative medicines and OTC pharmaceutical products from Teva and various third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States.</p>   <p align="justify"><strong><em>United States Gross Profit</em></strong></p>   <p align="justify"><strong>Gross profit from</strong> our United States segment in the fourth quarter of 2024 was $1,097 million, a decrease of 24%, compared to $1,444 million in the fourth quarter of 2023.</p>   <p align="justify"><strong>Gross profit margin</strong> for our United States segment in the fourth quarter of 2024 decreased to 55.6%, compared to 63.7% in the fourth quarter of 2023. This decrease was mainly due to an upfront payment received in the fourth quarter of 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, partially offset by a favorable mix of products, primarily driven by an increase in revenues from AUSTEDO and the sale of certain product rights.</p>   <p align="justify"><strong><em>United States Profit </em></strong></p>   <p align="justify">Profit from our United States segment consists of revenues less cost of sales, R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.</p>   <p align="justify"><strong>Profit</strong> from our United States segment in the fourth quarter of 2024 was $569 million, a decrease of 42% compared to $974 million in the fourth quarter of 2023. The higher profit in the fourth quarter of 2023 was mainly due to an upfront payment received in relation to the collaboration on our duvakitug (anti-TL1A) asset.</p>   <p align="justify"><strong>Europe Segment</strong></p>   <p align="justify">Our Europe segment includes the European Union, the United Kingdom and certain other European countries.</p>   <p align="justify">The following table presents revenues, expenses and profit for our Europe segment for the three months ended December 31, 2024 and 2023:</p>  <table align="left" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td class="hugin">&#160;</td><td colspan="6" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; "><strong>Three months ended December 31,</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions / % of Segment Revenues)</strong></td></tr><tr><td style="max-width:50%; width:50%; min-width:50%;;vertical-align: bottom ; ">Revenues</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1,353</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">100%</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1,344</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">100%</td></tr><tr><td style="vertical-align: bottom ; ">Cost of sales</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">561</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">41.4%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">561</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">41.7%</td></tr><tr><td style="vertical-align: bottom ; ">Gross profit</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">792</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">58.6%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">783</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">58.3%</td></tr><tr><td style="vertical-align: bottom ; ">R&amp;D expenses</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">56</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">4.2%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">52</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">3.9%</td></tr><tr><td style="vertical-align: bottom ; ">S&amp;M expenses</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">221</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">16.3%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">203</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">15.1%</td></tr><tr><td style="vertical-align: bottom ; ">G&amp;A expenses</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">75</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">5.6%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">67</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">5.0%</td></tr><tr><td style="vertical-align: bottom ; ">Other loss (income)</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#167;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#167;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#167;</td></tr><tr><td style="vertical-align: bottom ; ">Segment profit*</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">438</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">32.4%</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">461</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">34.3%</td></tr><tr><td colspan="7" style="vertical-align: bottom ; ">* Segment profit does not include amortization and certain other items.<br >&#167; Represents an amount less than $0.5 million or 0.5%, as applicable.</td></tr><tr><td colspan="7" style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>   <p><strong>Revenues</strong> from our Europe segment in the fourth quarter of 2024 were $1,353 million, an increase of 1%, or $9 million, compared to the fourth quarter of 2023. In local currency terms, revenues decreased by 2% compared to the fourth quarter of 2023. Our lower revenues in local currency terms in the fourth quarter of 2024 were mainly due to higher sales of certain product rights in the fourth quarter of 2023, partially offset by higher revenues from generic and OTC products as well as AJOVY.</p>   <p align="justify">In the fourth quarter of 2024, revenues were positively impacted by exchange rate fluctuations of $33 million, net of hedging effects, compared to the fourth quarter of 2023. Revenues in the fourth quarter of 2024, included $20 million from a positive hedging impact, which is included in &#8220;Other&#8221; in the table below. Revenues in the fourth quarter of 2023 included $20 million from a negative hedging impact, which is included in &#8220;Other&#8221; in the table below.</p>   <p align="justify"><strong><em>Revenues by Major Products and Activities</em></strong><br >The following table presents revenues for our Europe segment by major products and activities for the three months ended December 31, 2024 and 2023:</p>  <table align="left" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three months ended</strong><br ><strong>December 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Percentage</strong><br > <strong>Change</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024-2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td></tr><tr><td style="max-width:59%; width:59%; min-width:59%;;vertical-align: bottom ; ">Generic products (including OTC and biosimilars)</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; "><strong>&#160;</strong></td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:12%; width:12%; min-width:12%;;border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">979</td><td style="max-width:1%; width:1%; min-width:1%;;border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="max-width:1%; width:1%; min-width:1%;;border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:12%; width:12%; min-width:12%;;border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">938</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">4%</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">58</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">45</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">28%</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE</td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">50</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">56</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(11%)</td></tr><tr><td style="vertical-align: bottom ; ">Respiratory products</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">61</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">70</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(13%)</td></tr><tr><td style="vertical-align: bottom ; ">Other*</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">205</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">234</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(12%)</td></tr><tr><td style="vertical-align: bottom ; ">Total</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1,353</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1,344</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1%</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="7" style="vertical-align: top ; ">*Other revenues in the fourth quarter of 2024 and 2023 include the sale of certain product rights.</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="7" style="vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p align="justify"><strong>Generic products </strong>revenues (including OTC and biosimilar products) in our Europe segment in the fourth quarter of 2024, were $979 million, an increase of 4% compared to the fourth quarter of 2023. In local currency terms, revenues increased by 5%, mainly due to price increases as a result of market conditions such as inflationary pressures in certain markets, as well as higher revenues from recently launched products.</p>   <p align="justify"><strong>AJOVY </strong>revenues in our Europe segment in the fourth quarter of 2024 were $58 million, an increase of 28% in both U.S. dollars and local currency terms, compared to the fourth quarter of 2023. This increase was due to growth in volume.</p>   <p align="justify"><strong>COPAXONE</strong> revenues in our Europe segment in the fourth quarter of 2024 were $50 million, a decrease of 11% in both U.S. dollars and local currency terms, compared to the fourth quarter of 2023. This decrease was mainly due to price reductions and a decline in volume resulting from availability of alternative therapies and competing glatiramer acetate products.</p>   <p align="justify"><strong>Respiratory products</strong> revenues in our Europe segment in the fourth quarter of 2024 were $61 million, a decrease of 13% in both U.S. dollars and local currency terms, compared to the fourth quarter of 2023. This decrease was mainly due to net price reductions and lower volumes.</p>   <p align="justify"><strong><em>Europe Gross Profit </em></strong></p>   <p align="justify"><strong>Gross profit</strong> from our Europe segment in the fourth quarter of 2024 was $792 million, an increase of 1% compared to $783 million in the fourth quarter of 2023.</p>   <p align="justify"><strong>Gross profit margin</strong> for our Europe segment in the fourth quarter of 2024 increased to 58.6%, compared to 58.3% in the fourth quarter of 2023. This increase was mainly due to positive impact from hedging activities.</p>   <p align="justify"><strong><em>Europe Profit </em></strong></p>   <p align="justify">Profit from our Europe segment consists of revenues less cost of sales, R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.</p>   <p align="justify"><strong>Profit</strong> from our Europe segment in the fourth quarter of 2024 was $438 million, a decrease of 5%, compared to $461 million in the fourth quarter of 2023. This decrease was mainly due to higher S&amp;M expenses to support revenue growth.</p>   <p align="justify"><strong>International Markets Segment</strong></p>   <p align="justify">Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. The International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries.</p>   <p align="justify">As part of a recent shift in executive management responsibilities, commencing January 1, 2024, Canada is reported under our International Markets segment and is no longer included as part of our United States segment. Prior period amounts were recast to reflect this change.</p>   <p align="justify">On December 5, 2024, we announced that we entered into an agreement with JKI Co. Ltd., established by the fund managed and operated by private equity firm J-Will Partners Co. Ltd., to sell our business venture in Japan (the &#8220;BV&#8221;), which includes generic products and legacy products, with an expected closing date of April 1, 2025, subject to standard closing conditions.</p>   <p align="justify">Since the establishment of the BV and as of December 31, 2024, Teva holds 51% of the outstanding common stock of the BV, therefore consolidating the BV in our financial statements.</p>   <p align="justify">The following table presents revenues, expenses and profit for our International Markets segment for the three months ended December 31, 2024 and 2023:</p>  <table align="left" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td class="hugin">&#160;</td><td colspan="6" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; "><strong>Three months ended December 31,</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions / % of Segment Revenues)</strong></td></tr><tr><td style="max-width:50%; width:50%; min-width:50%;;vertical-align: bottom ; ">Revenues</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">661</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">100%</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">601</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">100%</td></tr><tr><td style="vertical-align: bottom ; ">Cost of sales</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">315</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">47.7%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">302</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">50.2%</td></tr><tr><td style="vertical-align: bottom ; ">Gross profit</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">346</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">52.3%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">299</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">49.8%</td></tr><tr><td style="vertical-align: bottom ; ">R&amp;D expenses</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">27</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">4.1%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">24</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">3.9%</td></tr><tr><td style="vertical-align: bottom ; ">S&amp;M expenses</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">137</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">20.7%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">134</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">22.2%</td></tr><tr><td style="vertical-align: bottom ; ">G&amp;A expenses</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">42</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">6.3%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">37</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">6.2%</td></tr><tr><td style="vertical-align: bottom ; ">Other loss (income)</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(1)</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#167;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(4)</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(0.7%)</td></tr><tr><td style="vertical-align: bottom ; ">Segment profit*</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">141</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">21.4%</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">109</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">18.1%</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="6" style="vertical-align: top ; ">* Segment profit does not include amortization and certain other items.<br >&#167; Represents an amount less than $0.5 million or 0.5%, as applicable.</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="6" style="vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p align="justify">&#160;</p>   <p align="justify"><strong>Revenues</strong> from our International Markets segment in the fourth quarter of 2024 were $661 million, an increase of 10% compared to the fourth quarter of 2023. In local currency terms, revenues increased by 17% compared to the fourth quarter of 2023, mainly due to revenues from the sale of certain product rights, higher revenues from generic products in most markets, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.</p>   <p align="justify">In the fourth quarter of 2024, revenues were negatively impacted by exchange rate fluctuations of $40 million, net of hedging effects, compared to the fourth quarter of 2023. Revenues in the fourth quarter of 2024 included $13 million from a positive hedging impact, compared to a negative hedging impact of $3 million in the fourth quarter of 2023, which are included in &#8220;Other&#8221; in the table below.</p>   <p align="justify"><em>Revenues by Major Products and Activities</em></p>   <p align="justify">The following table presents revenues for our International Markets segment by major products and activities for the three months ended December 31, 2024 and 2023:</p>  <table align="left" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td><td style="vertical-align: bottom ; "><strong>&#160;</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three months ended</strong><br ><strong>December 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Percentage</strong><br ><strong>Change</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024-2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="max-width:59%; width:59%; min-width:59%;;vertical-align: bottom ; ">Generic products (including OTC and biosimilars)</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:12%; width:12%; min-width:12%;;border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">497</td><td style="max-width:1%; width:1%; min-width:1%;;border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="max-width:12%; width:12%; min-width:12%;;border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">506</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(2%)</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">22</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">19</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">16%</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">9</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">12</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(25%)</td></tr><tr><td style="vertical-align: bottom ; ">AUSTEDO</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">7</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">5</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">50%</td></tr><tr><td style="vertical-align: bottom ; ">Other*</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">126</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">60</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">112%</td></tr><tr><td style="vertical-align: bottom ; ">Total</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">661</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">601</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">10%</td></tr><tr><td colspan="9" style="vertical-align: bottom ; ">*Other revenues in the fourth quarter of 2024 include the sale of certain product rights.</td></tr><tr><td colspan="9" style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>   <p><strong>Generic products</strong> revenues (including OTC and biosimilar products) in our International Markets segment were $497 million in the fourth quarter of 2024, a decrease of 2% compared to the fourth quarter of 2023. In local currency terms, revenues increased by 8% compared to the fourth quarter of 2023, mainly due to higher revenues in most markets, largely driven by price increases as a result of higher costs due to inflationary pressure in certain markets and higher volumes, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.</p>   <p align="justify"><strong>AJOVY </strong>was launched in certain markets in our International Markets segment, including in Canada, Japan, Australia, Israel, South Korea, Brazil and others. AJOVY revenues in our International Markets segment in the fourth quarter of 2024 were $22 million, compared to $19 million in the fourth quarter of 2023. In local currency terms, revenues increased by 22%, due to growth in existing markets in which AJOVY was launched.</p>   <p align="justify"><strong>COPAXONE</strong> revenues in our International Markets segment in the fourth quarter of 2024 were $9 million compared to $12 million in the fourth quarter of 2023. In local currency terms, revenues decreased by 16% mainly due to market share erosion and competition.</p>   <p align="justify"><strong>AUSTEDO </strong>was launched in China and Israel in 2021 and in Brazil in 2022, for the treatment of chorea associated with Huntington&#8217;s disease and for the treatment of tardive dyskinesia. In February 2024, we announced a strategic partnership for the marketing and distribution of AUSTEDO in China. We continue with additional submissions in various other markets.</p>   <p align="justify">AUSTEDO revenues in our International Markets segment in the fourth quarter of 2024 were $7 million. In local currency terms, revenues increased by 54%, substantially due to the launch of a strategic partnership in China.</p>   <p align="justify"><strong><em>International Markets Gross Profit </em></strong></p>   <p align="justify"><strong>Gross profit</strong> from our International Markets segment in the fourth quarter of 2024 was $346 million, an increase of 16% compared to $299 million in the fourth quarter of 2023.</p>   <p align="justify"><strong>Gross profit margin</strong> for our International Markets segment in the fourth quarter of 2024 increased to 52.3%, compared to 49.8% in the fourth quarter of 2023. This increase was mainly due to revenues from the sale of certain product rights, price increases largely as a result of inflationary pressures in certain markets, a positive hedging impact and a favorable mix of products, partially offset by regulatory price reductions and generic competition to off-patented products in Japan, as well as higher costs due to inflationary and other macroeconomic pressures.</p>   <p align="justify"><strong><em>International Markets Profit </em></strong></p>   <p align="justify">Profit from our International Markets segment consists of revenues less cost of sales, R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.</p>   <p align="justify">Profit from our International Markets segment in the fourth quarter of 2024 was $141 million, an increase of 30%, compared to $109 million in the fourth quarter of 2023. This increase was mainly due to higher gross profit, as mentioned above.</p>   <p align="justify"><strong>Other Activities </strong></p>   <p align="justify">We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our United States, Europe or International Markets segments described above.</p>   <p align="justify">On January 31, 2024, we announced that we intend to divest our API business (including its R&amp;D, manufacturing and commercial activities) through a sale. The intention to divest is in alignment with our Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of the potential divestiture or that a divestiture will be agreed or completed at all.</p>   <p align="justify">Revenues from <strong>other activities</strong> in the fourth quarter of 2024 were $241 million, a decrease of 2% in both U.S. dollars and local currency terms, compared to the fourth quarter of 2023.</p>   <p align="justify">API sales to third parties in the fourth quarter of 2024 were $145 million, flat compared to the fourth quarter of 2023, following a reallocation of an immaterial business within our other activities, in line with our intention to divest our API business.</p>   <p align="justify"><strong>2025 Non-GAAP Outlook </strong></p>  <table align="left" style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:50%; width:50%; min-width:50%;;vertical-align: middle;   text-align: left;   padding-left: 10.0px; border-bottom: solid black 1pt ; vertical-align: bottom ; ">$ billions, except diluted EPS or as noted</td><td style="max-width:50%; width:50%; min-width:50%;;vertical-align: middle;   text-align: left;   padding-left: 10.0px; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2025 Outlook</td></tr><tr><td style="vertical-align: bottom ; "><strong>Revenues*</strong></td><td style="vertical-align: middle;   text-align: left;   padding-left: 10.0px; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>16.8 &#8211;17.4</strong></td></tr><tr><td style="vertical-align: bottom ; ">AUSTEDO ($m)*</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1,900-2,050</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY ($m)*</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">~600</td></tr><tr><td style="vertical-align: bottom ; ">UZEDY ($m)*</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">~160</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE ($m)*</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">~370</td></tr><tr><td style="vertical-align: bottom ; "><strong>Operating Income</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>4.1 &#8211; 4.6</strong></td></tr><tr><td style="vertical-align: bottom ; "><strong>Adjusted EBITDA</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>4.5 &#8211; 5.0</strong></td></tr><tr><td style="vertical-align: bottom ; ">Finance Expenses ($m)</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">~900</td></tr><tr><td style="vertical-align: bottom ; ">Tax Rate</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">15% &#8211; 18%</td></tr><tr><td style="vertical-align: bottom ; ">Diluted EPS ($)</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2.35-2.65</td></tr><tr><td style="vertical-align: bottom ; "><strong>Free Cash Flow**</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>1.6 &#8211; 1.9</strong></td></tr><tr><td style="vertical-align: bottom ; ">CAPEX*</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">~0.5</td></tr><tr><td style="vertical-align: top ; ">Foreign Exchange</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;Volatile swings in FX can negatively impact revenue and income</td></tr><tr><td style="vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="vertical-align: bottom ; ">* Revenues and CAPEX presented on a GAAP basis.</td></tr><tr><td class="hugin" colspan="2">** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables</td></tr></table>  <p>&#160;</p>   <p align="justify"><strong>Annual Report on Form 10-K</strong></p>   <p align="justify">Teva's Annual Report on Form 10-K for the year ended December 31, 2024, which will be filed with the SEC, will include a complete analysis of the financial results for 2023 and will be available on Teva&#8217;s website: http://ir.tevapharm.com, as well as on the SEC&#8217;s website: http://www.sec.gov.</p>   <p align="justify"><strong>Conference Call</strong></p>   <p align="justify">Teva will host a conference call and live webcast along with a slide presentation on Wednesday, January 29, 2025 at 8:00 a.m. ET to discuss its fourth quarter and annual 2024 results and overall business environment. A question &amp; answer session will follow.</p>   <p align="justify">In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.</p>   <p align="justify">A live webcast of the call will be available on Teva's website at: http://ir.tevapharm.com/.</p>   <p align="justify">Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva&#8217;s website.</p>   <p align="justify"><strong>About Teva</strong></p>   <p align="justify">Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing its generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company&#8217;s global network of capabilities enables its ~37,000 employees across 57 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com<u>.</u></p>   <p align="justify">Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.</p>   <p align="justify"><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>   <p align="justify">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management&#8217;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;may,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe&#8221; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to:</p>   <ul type="disc"><li>our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies and changes in regulatory policy that may result in additional costs and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and the effectiveness of our patents and other measures to protect our intellectual property rights, including any potential challenges to our Orange Book patent listings in the U.S.;</li></ul>   <ul type="disc"><li>our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all;</li></ul>   <ul type="disc"><li>our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism, such as the ongoing conflict between Russia and Ukraine and the state of war declared in Israel; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively consummate such sales and divestitures, including our planned divestiture of our API business;</li></ul>   <ul type="disc"><li>compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; the effects of governmental and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; increased legal and regulatory action in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan<sup>&#174;</sup> (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement (DPA) with the U.S. Department of Justice; potential liability for intellectual property right infringement; product liability claims; failure to comply with complex Medicare, Medicaid and other governmental programs reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks; and the impact of ESG issues;</li></ul>   <ul type="disc"><li>the impact of the state of war declared in Israel and the military activity in the region, including the risk of disruptions to our operations and facilities, such as our manufacturing and R&amp;D facilities, located in Israel, the impact of our employees who are military reservists being called to active military duty, and the impact of the war on the economic, social and political stability of Israel;</li></ul>   <ul type="disc"><li>other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including the state of war declared in Israel and the conflict between Russia and Ukraine; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; and the impact of any future failure to establish and maintain effective internal control over our financial reporting;<br ><br >and other factors discussed in this press release, in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors&#8221; and &#8220;Forward Looking Statements,&#8221; and in other periodic reports we subsequently file with the SEC available on the SEC&#8217;s website: http://www.sec.gov. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.</li></ul>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:46%; width:46%; min-width:46%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:8%; width:8%; min-width:8%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:8%; width:8%; min-width:8%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:8%; width:8%; min-width:8%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:8%; width:8%; min-width:8%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:8%; width:8%; min-width:8%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="10" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong><u>Consolidated Statements of Income</u></strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="10" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong><u>(U.S. dollars in millions, except share and per share data)</u></strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="10" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Three months ended</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Year ended</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="6" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>December 31,</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>December 31,</strong><strong><br ></strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>(Unaudited)</strong></td><td style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; "><strong>2024</strong></td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; "><strong>2023</strong></td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; "><strong>2023</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Net revenues</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,229</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,457</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">16,544</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">15,846</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Cost of sales</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,109</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,041</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8,481</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8,200</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Gross profit</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,120</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,416</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8,064</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">7,645</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Research and development expenses</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">248</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">227</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">998</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">953</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Selling and marketing expenses</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">650</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">610</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,541</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,336</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">General and administrative expenses</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">302</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">291</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,161</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1162</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Intangible assets impairments</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">81</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">61</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">251</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">350</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Goodwill impairment</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">280</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">-</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,280</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">700</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Other asset impairments, restructuring and other items</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">457</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">443</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,388</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">718</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Legal settlements and loss contingencies</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">123</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">34</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">761</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,043</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Other (income) loss</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(6</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(14&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(49&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Operating income (loss)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(29&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">755</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(303&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">433</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Financial expenses, net</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">218</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">249</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">981</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,057</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Income (loss) before income taxes</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(247&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">507</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1,284&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(624&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Income taxes (benefit)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">29</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">43</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">676</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(7&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Share in (profits) losses of associated companies, net</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(2&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Net income (loss)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(275&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">465</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1,959&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(615&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Net income (loss) attributable to non-controlling interests</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(58&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(320&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(56&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Net income (loss) attributable to Teva</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(217&#160;</td><td style="border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">461</td><td style="border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1,639&#160;</td><td style="border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(559&#160;</td><td style="border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-left: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Earnings (loss) per share attributable to Teva:</td><td style="vertical-align: bottom ; ">Basic&#160;&#160;&#160; ($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(0.19</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">0.41</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1.45</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(0.50</td><td style="border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-left: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Diluted&#160; ($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(0.19</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">0.41</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1.45</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(0.50</td><td style="border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-left: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Weighted average number of shares (in millions):</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Basic</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,133</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,121</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,131</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,119</td><td style="border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Diluted</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,133</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,137</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,131</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,119</td><td style="border-bottom: solid black 1pt ; border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-left: solid black 1pt ; vertical-align: bottom ; ">Non-GAAP net income attributable to Teva for diluted earnings per share:*</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">816</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,135</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,860</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,898</td><td style="border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-left: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-left: solid black 1pt ; vertical-align: bottom ; ">Non-GAAP earnings per share attributable to Teva:*</td><td style="vertical-align: bottom ; ">Diluted ($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">0.71</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1.00</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2.49</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2.56</td><td style="border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-left: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-left: solid black 1pt ; vertical-align: bottom ; ">Non-GAAP average number of shares (in millions):</td><td style="vertical-align: bottom ; ">Diluted</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,157</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,137</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,150</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,131</td><td style="border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; border-right: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Amounts may not add up due to rounding.</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#167; Represents an amount less than $0.5 million.</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">* See reconciliation attached.</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong><u>Condensed Consolidated Balance Sheets</u></strong><strong><u>&#160;</u></strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><u>(U.S. dollars in millions)</u></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong><u>(Audited)</u></strong></td></tr><tr><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:73%; width:73%; min-width:73%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>December 31,</strong></td><td style="vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>December 31,</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>ASSETS</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>&#160;</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Current assets:</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Cash and cash equivalents</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,300</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,226</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: top ; ">Accounts receivables, net of allowance for credit losses of $78 million and $95 million as of December 31, 2024 and December 31, 2023</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,059</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,408</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Inventories</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,007</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4,021</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Prepaid expenses</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,006</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,255</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Other current assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 409</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 504</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Assets held for sale</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,771</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 70</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Total current assets</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 12,552</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 12,485</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Deferred income taxes</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,799</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,812</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Other non-current assets</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 462</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 470</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Property, plant and equipment, net</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4,581</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 5,750</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Operating lease right-of-use assets</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 367</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 397</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Identifiable intangible assets, net</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4,418</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 5,387</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Goodwill</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 15,147</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 17,177</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Total assets</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 39,326</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 43,479</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>LIABILITIES &amp; EQUITY</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Current liabilities:</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Short-term debt</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,781</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,672</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Sales reserves and allowances</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,678</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,535</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Trade payables</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2,203</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2,602</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Employee-related obligations</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 624</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 611</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Accrued expenses</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2,792</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2,771</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Other current liabilities</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,020</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,044</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Liabilities held for sale</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 698</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 13</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Total current liabilities</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 12,796</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 12,247</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Long-term liabilities:</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Deferred income taxes</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 483</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 606</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Other taxes and long-term liabilities</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4,028</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4,019</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Senior notes and loans</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 16,002</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 18,161</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Operating lease liabilities</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 296</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 320</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Total long-term liabilities</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 20,809</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 23,106</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Redeemable non-controlling interests</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 340</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;-&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Equity:</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Teva shareholders&#8217; equity:</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 5,373</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 7,506</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Non-controlling interests</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 7</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 620</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Total equity</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 5,380</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 8,126</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; "><strong>Total liabilities and equity</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 39,326</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 43,479</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="12" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>TEVA PHARMACEUTICAL INDUSTRIES LIMITED</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="12" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="12" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. dollars in millions)</strong><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="max-width:53%; width:53%; min-width:53%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Year ended</strong><strong><br ></strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three months ended</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong><strong><br ></strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong><strong><br ></strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(Unaudited)</strong><strong>&#160;</strong>&#160;&#160;&#160;&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(Audited)</strong><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(Audited)</strong><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(Unaudited)</strong><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(Unaudited)</strong><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Operating activities:</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Net income (loss)</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (1,959</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (615</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (275</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 465</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Adjustments to reconcile net income (loss) to net cash provided by operations:</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Impairment of goodwil</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,280</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 700</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 280</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Impairment of long-lived assets and assets held for sale</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,275</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 378</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 517</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 68</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Depreciation and amortization</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,059</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,153</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 269</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 266</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Net change in operating assets and liabilities</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (435</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (72</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (246</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 292</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Deferred income taxes &#8212; net and uncertain tax positions</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (634</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (317</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 32</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 34</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Stock-based compensation</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 123</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 121</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 34</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 28</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Net loss (gain) from sale of business and long-lived assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (22</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (41</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (10</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: bottom ; ">Other items *&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 560</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 61</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (37</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 41</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>Net cash provided by (used in) operating activities</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,247</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,368</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 575</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,184</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Investing activities:</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Beneficial interest collected in exchange for securitized trade receivables</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,291</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,477</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 340</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 421</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Purchases of property, plant and equipment and intangible assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (498</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (526</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (129</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (120</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: bottom ; ">Proceeds from sale of business and long lived assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 43</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 68</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Purchases of investments and other assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (71</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (46</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (15</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (2</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: bottom ; ">Proceeds from sale of investments</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 40</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Acquisitions of businesses, net of cash acquired.</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (15</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Other investing activities</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (5</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Net cash provided by (used in) investing activities</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 792</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 968</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 202</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>&#160;</strong></td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 301</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Financing activities:</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Repayment of senior notes and loans and other long term liabilities</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (1,641</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (4,152</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (685</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Proceeds from senior notes, net of issuance costs</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2,451</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Proceeds from short term debt</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 700</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Repayment of short term debt</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (700</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (500</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: bottom ; ">Purchase of shares from non-controlling interests&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (64</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Dividends paid to non-controlling interests&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (78</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Other financing activities</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (8</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (212</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 10</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (76</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: bottom ; "><strong>Net cash provided by (used in) financing activities</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (1,791</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (1,913</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (675</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (576</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: bottom ; "><strong>Translation adjustment on cash and cash equivalents</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (174</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (30</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (121</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 68</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>Net change in cash, cash equivalents and restricted cash</strong></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 74</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 393</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (19</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 977</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>Balance of cash, cash equivalents and restricted cash at beginning of year</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,227</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2,834</td><td style="border-bottom: solid black 1pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,319</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2,250</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>Balance of cash, cash equivalents and restricted cash at end of year</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,300</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,227</td><td style="border-bottom: double black 3pt ; text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,300</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,227</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Cash and cash equivalents</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,300</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,226</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,300</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,226</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Restricted cash included in other current assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>Total cash, cash equivalents and restricted cash shown in the statements of cash flows</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,300</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,227</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,300</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3,227</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="13" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Reconciliation of net income (loss) attributable to Teva</strong><strong>&#160;</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="13" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>to Non-GAAP net income (loss) attributable to Teva</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:51%; width:51%; min-width:51%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;Three months ended&#160;&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="4" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;Year ended&#160;&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;December 31,&#160;&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="4" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;December 31,&#160;&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><em>($ in millions except per share amounts)</em></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;2024&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2023</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;2024&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2023</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Net income (Loss) attributable to Teva</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (217</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 461</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;(1,639</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (559</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Increase (decrease) for excluded items:</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Amortization of purchased intangible assets</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 144</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 144</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160; 588</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 616</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Legal settlements and loss contingencies<sup>(1)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 123</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 34</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160; 761</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,043</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Goodwill impairment<sup>(2)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 280</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160; 1,280</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 700</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Impairment of long-lived assets<sup>(3)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 517</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 68</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160; 1,275</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 378</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Restructuring costs</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 22</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 18</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 74</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 111</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Equity compensation</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 34</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 28</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160; 123</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 121</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Contingent consideration<sup>(4)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (2</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 408</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160; 303</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 548</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Loss (Gain) on sale of business</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 6</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160; (15</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (3</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Accelerated depreciation</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 5</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 6</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 13</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 80</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Financial expenses&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 13</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 13</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 49</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 66</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Items attributable to non-controlling interests<sup>(3)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (63</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (1</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160; (339</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (92</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Other non-GAAP items<sup>(5)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 67</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 83</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160; 229</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 335</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Corresponding tax effects and unusual tax items<sup>(6)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (114</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (128</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160; 157</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (446</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Non-GAAP net income attributable to Teva</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 816</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160; 1,135</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160; 2,860</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2,898</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Non-GAAP tax rate<sup>(7)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">14.8</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">13.1</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">15.3</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">13.0</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">GAAP diluted earnings (loss) per share attributable to Teva</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (0.19</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 0.41</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160; ($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160; (1.45</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (0.50</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">EPS difference<sup>(8)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 0.90</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 0.59</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160; 3.94</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3.06</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Non-GAAP diluted EPS attributable to Teva<sup>(8)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 0.71</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1.00</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160; ($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160; 2.49</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2.56</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Non-GAAP average number of shares (in millions)<sup>(8)</sup></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,157</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160; 1,137</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160; 1,150</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,131</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">(1)</td><td colspan="15" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">Adjustments for legal settlements and loss contingencies in 2024 were mainly related to a legal expenses of $357 million recorded in connection with a decision by the European Commission in its antitrust investigation into COPAXONE, and to an update to the estimated settlement provision of $278 million for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore). Adjustments for legal settlements and loss contingencies in 2023 were mainly related to an update to the estimated provision of $370 million related to the DOJ patient assistance program litigation, an update to the estimated settlement provision of $269 million related to the remaining opioid cases, the provision of $207 million relating to the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products and the provision of $100 million related to the settlement of the reverse-payment antitrust litigation over certain HIV medicines.&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">(2)</td><td colspan="15" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">During the fourth quarter of 2024 a goodwill impairment charge of $280 million was recorded related to our API reporting unit. During the year ended December 31, 2024 goodwill impairment charges of $1,280 million were recorded related to our API reporting unit. During the year ended December 31, 2023 goodwill impairment charges of $700 million were recorded related to our International Markets reporting unit.</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">(3)</td><td colspan="15" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">Adjustments for impairment of long-lived assets and items attributable to non-controlling interests, in the fourth quarter of 2024 primarily consisted of $129 million and $63 million, respectively, related to the classification of the business venture in Japan as held for sale. In addition, in the fourth quarter of 2024 we recognized an impairment of $275 million related to the classification of our API business (including its R&amp;D, manufacturing and commercial activities) as held for sale. Adjustments for impairment of long-lived assets and items attributable to non-controlling interests, for the year ended December 31, 2024 primarily consisted of $689 million and $339 million, respectively, related to the classification of the business venture in Japan as held for sale. In addition, in 2024 we recognized an impairment of $275 million related to the classification of our API business (including its R&amp;D, manufacturing and commercial activities) as held for sale.&#160;&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">(4)</td><td colspan="15" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">During the fourth quarter of 2024 and 2023 adjustments for contingent consideration primarily related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of Revlimid<sup>&#174;</sup>), of $3 million and $311 million, respectively. During the year ended December 31, 2024 and 2023 adjustments for contingent consideration primarily related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of Revlimid<sup>&#174;</sup>), of $270 million and $422 million, respectively.&#160;&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">(5)</td><td colspan="15" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other unusual events.&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">(6)</td><td colspan="15" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">Adjustments for corresponding tax effects and unusual tax items for the year ended December 31, 2024, include a tax item in an amount of $495 million related to the settlement agreement with the ITA to settle certain litigation with respect to taxes payable for the Company&#8217;s taxable years 2008 through 2020.&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">(7)</td><td colspan="15" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above.&#160;&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">(8)</td><td colspan="15" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">EPS difference and diluted non-GAAP EPS are calculated by dividing our non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares.</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td colspan="15" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="6" style="vertical-align: bottom ; "><strong>Reconciliation of gross profit to Non-GAAP gross profit</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:55%; width:55%; min-width:55%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Three months ended&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Year ended&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">December 31,&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">December 31,&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><em>($ in millions)</em></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2024</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2023</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2024</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2023</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>GAAP gross profit</strong></td><td style="vertical-align: bottom ; ">($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,120</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,416</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8,064</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">7,645</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: middle ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>GAAP gross profit margin</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">50.1</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">54.2</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">48.7</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">48.2</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: middle ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Increase (decrease) for excluded items:<sup>(1)</sup></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Amortization of purchased intangible assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">135</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">129</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">543</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">549</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Costs related to regulatory actions taken in facilities</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Equity compensation</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">5</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">23</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">19</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Accelerated Depreciation</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">5</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">6</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">13</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">80</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Other non-GAAP items</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">51</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">35</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">164</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">173</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Non-GAAP gross profit</strong></td><td style="vertical-align: bottom ; ">($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,319</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,592</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8,814</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8,470</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Non-GAAP gross profit margin</strong><sup><strong>(2)</strong></sup></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">54.8</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">58.2</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">53.3</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">53.5</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="12" style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><sup>(1)</sup>For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td colspan="12" style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><sup>(2)</sup>Non-GAAP gross profit margin is non-GAAP gross profit as a percentage of revenue.</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td colspan="10" style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="10" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Reconciliation of operating income (loss) to Non-GAAP operating income (loss)</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="10" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:55%; width:55%; min-width:55%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;Three months ended&#160;&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">Year ended,&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;December 31,&#160;&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;December 31,&#160;&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><em>($ in millions)</em></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2024</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2023</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2024</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2023</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Operating income (loss)</strong></td><td style="vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (29</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 755</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (303</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 433</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Operating margin</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(0.7</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">17.0</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1.8</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2.7</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">Increase (decrease) for excluded items: <sup>(1)</sup></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Amortization of purchased intangible assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 144</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 144</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 588</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 616</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Legal settlements and loss contingencies</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 123</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 34</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 761</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,043</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Goodwill impairment</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 280</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,280</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 700</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Impairment of long-lived assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 517</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 68</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,275</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 378</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Restructuring costs</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 22</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 18</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 74</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 111</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Equity compensation</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 34</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 28</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 123</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 121</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Contingent consideration</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (2</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 408</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 303</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 548</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Loss (gain) on sale of business</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 6</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; -&#160;&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (15</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (3</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Accelerated depreciation</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 5</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 6</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 13</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 80</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Other non-GAAP items</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 67</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 84</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 229</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 336</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Non-GAAP operating income (loss)</strong></td><td style="vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,168</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,546</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4,329</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 4,361</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>Non-GAAP operating margin</strong><sup><strong>(2)</strong></sup></td><td style="vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">27.6</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">34.7</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;($)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">26.2</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">27.5</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">%</td></tr><tr><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="10" style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><sup>(1) </sup>For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td colspan="10" style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><sup>(2) </sup>Non-GAAP operating margin is Non-GAAP operating income as a percentage of revenues.&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr><tr><td colspan="5" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="10" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Reconciliation of net income (loss) to adjusted EBITDA</strong><strong><br ></strong></td></tr><tr><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:42%; width:42%; min-width:42%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three months ended</strong><strong><br ></strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Year ended</strong><strong><br ></strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong><strong><br ></strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="3" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong><strong><br ></strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">($ in millions)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>Net income (loss)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>(275</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>)</strong></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>465</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>(1,959</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>)</strong></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>(615</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>)</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="vertical-align: bottom ; ">Increase (decrease) for excluded items:<sup>(1)</sup></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Financial expenses</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">218</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">249</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">981</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,057</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Income taxes</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">29</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">43</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">676</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(7</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="vertical-align: bottom ; ">Share in profits (losses) of associated companies &#8211;net</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(2</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Depreciation</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">119</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">120</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">465</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">537</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Amortization</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">144</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">144</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">588</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">616</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>EBITDA</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>235</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>1,020</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>750</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>1,585</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="vertical-align: bottom ; ">Legal settlements and loss contingencies</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">123</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">34</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">761</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,043</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Goodwill impairment</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">280</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">-</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,280</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">700</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Impairment of long lived assets</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">517</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">68</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,275</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">378</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Restructuring costs</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">22</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">18</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">74</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">111</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Equity compensation</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">34</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">28</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">123</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">121</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Contingent consideration</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(2</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">408</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">303</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">548</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Loss (Gain) on sale of Business</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">6</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">-</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(15</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(3</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">Other non-GAAP items</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">67</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">84</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">229</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">335</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="2" style="vertical-align: bottom ; "><strong>Adjusted EBITDA</strong></td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>1,282</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>1,660</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>4,781</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>4,818</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="10" style="vertical-align: bottom ; "><sup>(1)</sup>For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="10" style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:29%; width:29%; min-width:29%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="17" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Segment Information</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>United States</strong></td><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Europe</strong></td><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>International Markets</strong></td></tr><tr><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Three months ended December 31,</strong></td><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Three months ended December 31,</strong></td><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Three months ended December 31,</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Revenues</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,975</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,266</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,353</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,344</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">661</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">601</td></tr><tr><td style="vertical-align: bottom ; ">Cost of sales</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">877</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">822</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">561</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">561</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">315</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">302</td></tr><tr><td style="vertical-align: bottom ; ">Gross profit</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,097</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,444</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">792</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">783</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">346</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">299</td></tr><tr><td style="vertical-align: bottom ; ">R&amp;D expenses</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">158</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">144</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">56</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">52</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">27</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">24</td></tr><tr><td style="vertical-align: bottom ; ">S&amp;M expenses</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">260</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">238</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">221</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">203</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">137</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">134</td></tr><tr><td style="vertical-align: bottom ; ">G&amp;A expenses</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">109</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">90</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">75</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">67</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">42</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">37</td></tr><tr><td style="vertical-align: bottom ; ">Other income</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#167;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(4)</td></tr><tr><td style="vertical-align: bottom ; ">Segment profit</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">569</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">974</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">438</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">461</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">141</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">109</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="18" style="vertical-align: bottom ; ">&#167; Represents an amount less than $0.5 million.</td></tr><tr><td colspan="18" style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:29%; width:29%; min-width:29%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="18" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Segment Information</strong></td></tr><tr><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>United States</strong></td><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Europe</strong></td><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>International Markets</strong></td></tr><tr><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Year ended December 31,</strong></td><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Year ended December 31,</strong></td><td style="vertical-align: middle ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Year ended December 31,</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Revenues</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">8,034</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">7,731</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">5,103</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,837</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,463</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,351</td></tr><tr><td style="vertical-align: bottom ; ">Cost of sales</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,646</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,421</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,197</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,111</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,229</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,191</td></tr><tr><td style="vertical-align: bottom ; ">Gross profit</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,388</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,310</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,905</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,726</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,235</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,160</td></tr><tr><td style="vertical-align: bottom ; ">R&amp;D expenses</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">633</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">604</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">229</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">220</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">112</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">104</td></tr><tr><td style="vertical-align: bottom ; ">S&amp;M expenses</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,049</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">938</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">826</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">767</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">534</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">487</td></tr><tr><td style="vertical-align: bottom ; ">G&amp;A expenses</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">410</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">378</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">272</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">263</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">150</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">142</td></tr><tr><td style="vertical-align: bottom ; ">Other income</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#167;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(5)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(2)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(2)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(39)</td></tr><tr><td style="vertical-align: bottom ; ">Segment profit</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,296</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,394</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,575</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,478</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">440</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">465</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Reconciliation of our segment profit</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>to consolidated income (loss) before income taxes</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three months ended</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="max-width:72%; width:72%; min-width:72%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S.$ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">United States profit</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">569</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">974</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Europe profit</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">438</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">461</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">International Markets profit</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">141</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">109</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Total reportable segment profit</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,148</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,544</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Profit (loss) of other activities</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">19</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,168</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,546</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Amounts not allocated to segments:</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Amortization</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">144</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">144</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Other asset impairments, restructuring and other items</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">458</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">443</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Goodwill impairment</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">280</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">-</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Intangible asset impairments</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">81</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">61</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Legal settlements and loss contingencies</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">123</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">34</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Other unallocated amounts</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">110</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">108</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Consolidated operating income (loss)</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(29)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">755</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Financial expenses - net</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">218</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">249</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Consolidated income (loss) before income taxes</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(247)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">507</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="7" style="text-align: center ;  vertical-align: middle; vertical-align: top ; "><strong>Reconciliation of our segment profit</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="7" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>to consolidated income (loss) before income taxes</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Year ended</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="max-width:71%; width:71%; min-width:71%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S.$ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">United States profit</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,296</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,394</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Europe profit</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,575</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,478</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">International Markets profit</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">440</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">465</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Total reportable segment profit</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,311</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,338</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Profit (loss) of other activities</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">18</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">24</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Total segment profit</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,329</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4,361</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Amounts not allocated to segments:</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Amortization</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">588</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">616</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Other asset impairments, restructuring and other items</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,388</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">718</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Goodwill impairment</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,280</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">700</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Intangible asset impairments</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">251</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">350</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Legal settlements and loss contingencies</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">761</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,043</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle;   text-align: left;   padding-left: 30.0px; vertical-align: bottom ; ">Other unallocated amounts</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">364</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">502</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Consolidated operating income (loss)</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(303)</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">433</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Financial expenses - net</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">981</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,057</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Consolidated income (loss) before income taxes</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(1,284)</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(624)</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:65%; width:65%; min-width:65%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="9" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Segment revenues by major products and activities</strong></td></tr><tr><td colspan="9" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three months ended</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Percentage</strong><br ><strong>Change</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023-2024</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S.$ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>United States segment</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Generic products</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">674</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">667</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">1%</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">63</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">57</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">11%</td></tr><tr><td style="vertical-align: bottom ; ">AUSTEDO</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">518</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">408</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">27%</td></tr><tr><td style="vertical-align: bottom ; ">BENDEKA/TREANDA</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">41</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">52</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(21%)</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">63</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">72</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(13%)</td></tr><tr><td style="vertical-align: bottom ; ">UZEDY</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">43</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">9</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">N/A</td></tr><tr><td style="vertical-align: bottom ; ">Anda</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">402</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">394</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">2%</td></tr><tr><td style="vertical-align: bottom ; ">Other*</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">171</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">607</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(72%)</td></tr><tr><td style="vertical-align: bottom ; "><strong>Total</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>1,975</strong></td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>2,266</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(13%)</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="9" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">*Other revenues in the fourth quarter of 2024 include the sale of certain product rights. Other revenues in 2023 were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on our duvakitug (anti-TL1A) asset.</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three months ended</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Percentage</strong><br ><strong>Change</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023-2024</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S.$ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>Europe segment</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Generic products</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">979</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">938</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">4%</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">58</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">45</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">28%</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">50</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">56</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(11%)</td></tr><tr><td style="vertical-align: bottom ; ">Respiratory products</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">61</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">70</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(13%)</td></tr><tr><td style="vertical-align: bottom ; ">Other*</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">205</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">234</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(12%)</td></tr><tr><td style="vertical-align: bottom ; "><strong>Total</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>1,353</strong></td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>1,344</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>1%</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="9" style="vertical-align: bottom ; ">*Other revenues in the fourth quarter of 2024 and 2023 include the sale of certain product rights.</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three months ended</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Percentage</strong><br ><strong>Change</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023-2024</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S.$ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>International Markets segment</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Generic products</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">497</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">506</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(2%)</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">22</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">19</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">16%</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">9</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">12</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(25%)</td></tr><tr><td style="vertical-align: bottom ; ">AUSTEDO</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">7</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">5</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">50%</td></tr><tr><td style="vertical-align: bottom ; ">Other*</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">126</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">60</td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">112%</td></tr><tr><td style="vertical-align: bottom ; "><strong>Total</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>661</strong></td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>601</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>10%</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="9" style="vertical-align: bottom ; ">*Other revenues in the fourth quarter of 2024 include the sale of certain product rights.</td></tr><tr><td colspan="9" style="vertical-align: middle ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:65%; width:65%; min-width:65%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:10%; width:10%; min-width:10%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="9" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Segment revenues by major products and activities</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Year ended</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Percentage</strong><br ><strong>Change</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024-2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S.$ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>United States segment</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Generic products</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,599</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,138</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">15%</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">207</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">211</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(2%)</td></tr><tr><td style="vertical-align: bottom ; ">AUSTEDO</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,642</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,225</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">34%</td></tr><tr><td style="vertical-align: bottom ; ">BENDEKA / TREANDA</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">168</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">237</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(29%)</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">242</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">297</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(18%)</td></tr><tr><td style="vertical-align: bottom ; ">UZEDY</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">117</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">23</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">N/A</td></tr><tr><td style="vertical-align: bottom ; ">Anda</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,536</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,577</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(3%)</td></tr><tr><td style="vertical-align: bottom ; ">Other*</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">523</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,025</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(49%)</td></tr><tr><td style="vertical-align: bottom ; "><strong>Total</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>8,034</strong></td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>7,731</strong></td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>4%</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="9" style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">*Other revenues in 2024 include the sale of certain product rights. Other revenues in 2023 were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on our duvakitug (anti-TL1A) asset.</td></tr><tr><td style="vertical-align: middle ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Year ended</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Percentage</strong><br ><strong>Change</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024-2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S.$ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; "><strong>Europe segment</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Generic products</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,926</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">3,664</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">7%</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">216</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">160</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">34%</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">213</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">231</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(8%)</td></tr><tr><td style="vertical-align: bottom ; ">Respiratory products</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">244</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">265</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(8%)</td></tr><tr><td style="vertical-align: bottom ; ">Other*</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">504</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">516</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(2%)</td></tr><tr><td style="vertical-align: bottom ; "><strong>Total</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>5,103</strong></td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>4,837</strong></td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>5%</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="9" style="vertical-align: bottom ; ">*Other revenues in 2024 and 2023 include the sale of certain product rights.</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Year ended</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>Percentage</strong><br ><strong>Change</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024-2023</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S.$ in millions)</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="3" style="vertical-align: bottom ; "><strong>International Markets segment</strong></td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Generic products</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,937</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,932</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">0%</td></tr><tr><td style="vertical-align: bottom ; ">AJOVY</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">84</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">63</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">33%</td></tr><tr><td style="vertical-align: bottom ; ">COPAXONE</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">48</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">63</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">(24%)</td></tr><tr><td style="vertical-align: bottom ; ">Austedo</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">46</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">15</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">199%</td></tr><tr><td style="vertical-align: bottom ; ">Other*</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">349</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">278</td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">25%</td></tr><tr><td style="vertical-align: bottom ; "><strong>Tota</strong></td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>2,463</strong></td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>2,351</strong></td><td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>5%</strong></td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="8" style="vertical-align: bottom ; ">*Other revenues in 2024 include the sale of certain product rights.</td><td style="vertical-align: bottom ; ">&#160;</td></tr><tr><td colspan="8" style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Free cash flow reconciliation</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: middle ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: middle ; ">&#160;</td></tr><tr><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="max-width:73%; width:73%; min-width:73%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle ; ">&#160;</td><td colspan="6" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Three months ended December 31,</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Net cash provided by (used in) operating activities</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">575</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,184</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: top ; ">Beneficial interest collected in exchange for securitized account receivables</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">340</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">421</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Purchases of property, plant and equipment and intangible assets</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(129</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(120</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: bottom ; ">Proceeds from divestitures of businesses and other assets</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">4</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">-</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Free cash flow</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">790</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,486</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td><td style="vertical-align: bottom ; ">&#160;</td></tr></table>  <p>&#160;</p>  <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Free cash flow reconciliation</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: middle ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: middle ; ">&#160;</td></tr><tr><td colspan="6" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="max-width:73%; width:73%; min-width:73%;;text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="max-width:12%; width:12%; min-width:12%;;border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: middle ; ">&#160;</td><td colspan="6" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; "><strong>Year ended December 31</strong>&#160;</td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: middle ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td colspan="2" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>2023</strong></td><td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td colspan="5" style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><strong>(U.S. $ in millions)</strong></td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: center ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Net cash provided by (used in) operating activities</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,247</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,368</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Beneficial interest collected in exchange for securitized account receivables</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,291</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">1,477</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Purchases of property, plant and equipment and intangible assets</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(498</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(526</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td></tr><tr><td style="vertical-align: bottom ; ">Acquisition of businesses, net of cash acquired</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">(15</td><td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; ">)</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">-</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Proceeds from divestitures of businesses and other assets</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">43</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">68</td><td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">Free cash flow</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,068</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">$</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">2,387</td><td style="border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr><tr><td style="vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td><td style="text-align: right ;  vertical-align: middle; vertical-align: bottom ; ">&#160;</td></tr></table>  <p><strong>Teva Media Inquiries</strong><strong><br > </strong><strong><u>TevaCommunicationsNorthAmerica@tevapharm.com</u></strong></p>   <p><strong>Teva Investor Relations Inquires</strong><strong><br > </strong><strong><u>TevaIR@Tevapharm.com</u></strong></p>   <p>A PDF accompanying this announcement is available at&#160;http://ml-eu.globenewswire.com/Resource/Download/b66d129f-8d07-41e1-bf88-270e8ff2d21d</p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>gnw-20190101.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:gnw="http://globenewswire.com/20190101" elementFormDefault="qualified" targetNamespace="http://globenewswire.com/20190101">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://globenewswire.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="gnw-20190101_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gnw-20190101_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gnw-20190101_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>gnw-20190101_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://globenewswire.com/role/Cover" xlink:href="gnw-20190101.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://globenewswire.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaapPreferredClassAMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredClassAMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="55" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>gnw-20190101_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>gnw-20190101_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="no"?>
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://globenewswire.com/role/Cover" xlink:href="gnw-20190101.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://globenewswire.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45350663551840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 29,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TEVA PHARMACEUTICAL INDUSTRIES LIMITED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">124 Dvora Hanevi&#8217;a Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6944020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-914-8213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one Ordinary Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TEVA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  <X/5H'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  '.#U:A^ X$.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G21%P;#-1?'4@F!!\1:2:1O<[(9D9+=O[VYLMX@^@,?,_/GF
M&YC&1F7[A,^ICYC(8[X90]ME9>.:'8FB LCVB,'D>DIT4W/?IV!H>J8#1&,_
MS %!<GX' <DX0P9F8!47(M.-L\HF--2G,][9!1\_4UM@S@*V&+"C#*(6P/0\
M,9[&MH$K8(81II"_"^@68JG^B2T=8.?DF/V2&H:A'E8E-^T@X&V[>2GK5K[+
M9#J+TZ_L%9TBKMEE\NOJX7'WQ+3D\K;BHI+W.R$5YTK(]]GUA]]5./3.[_T_
M-KX(Z@9^W87^ E!+ P04    "  '.#U:F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M  <X/5I;>(MJ2@0   @0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9=K;^(X%(;_BI611KM2VUR@7#J 1(%.V:$M*G1&NZO]8!(#UB1VUC;0_OL]
M#C1A9\()TP\E3GS>/#X^>6UW=E)]UVO&#'E-8J&[SMJ8],9U=;AF"=57,F4"
MGBRE2JB!IEJY.E6,1EE0$KN!YS7<A'+A]#K9O:GJ=>3&Q%RPJ2)ZDR14O=VR
M6.ZZCN^\WWCFJ[6Q-]Q>)Z4K-F/F)9TJ:+FY2L03)C27@BBV[#I]_^8VJ-F
MK,=7SG;ZZ)K8H2RD_&X;XZCK>):(Q2PT5H+"SY8-6!Q;)>#X]R#JY.^T@<?7
M[^IWV>!A, NJV4#&WWADUEVGY9"(+>DF-L]R=\\. [JV>J&,=?:?[/9]ZW6'
MA!MM9'((!H*$B_TO?3TDXBB@<7TB(#@$!!GW_D49Y9 :VNLHN2/*]@8U>Y$-
M-8L&."[LK,R,@J<<XDQO(+=,=5P#4O:&&Q[";O=AP8FP/ZBX(D'[@@1></W_
M<!<(<HP@QP@RO1J&0?[N+[11,%'_E!'M%>KE"K9Z;W1*0]9UH#PU4UOF]#Y^
M\!O>)X2OEO/5,/7>4(8;J$5#YF\I*X/#PUN77Q"(>@Y11U7Z0!!E%'<Q7951
MX/%+&FN&<%SG'-?G)6/*%)<1&8F(0/&5Y@57RLNHJHX:.5H#%1P)P\T;N>,Q
M(X^;9%%>V[B&Y_F7?L-OUA&>9L[3/(?GF:VXK6S(V2--2A.%Z\Q'7_MD>M]_
M?N@/1B_S\: _(>/'X<ML_CP>S<AD_#">CX8(<"L';IT#/(#I530F8Q&Q5_*%
MO94AXTH>_+7\5J/50+#:.5;['*RQ"*5*I:+6T2_(S$#5$:G(0&Z %[!E5)I<
M7'Q20PA]KW!2[QS&?A2!_^B+]PLR@7[D292"54CZ09T,MS!><D\%V_*/'UJ!
MW_Q$8>0*'!_#/EH _%_"'M@6Y'0N=Z(4&9>;LYCTMWR+L16K@H^:^L]L^WDN
MQ<*5QA,,J%@&?-S(?P2:2FW@,_F+IR=KKT*QT:[7O<##Z(KUP<<-/INZ/FS.
M3L/@ NUF@($4"X2/^_I$AI"5Z5H*S(8K1&J7;;]^"06/?I[%RN#CMOY-<6.8
M@-0DR4;P,/,07<J%"U4MHWZQ./BXJ\]DS$-NN%B1!W RQ6E<RH.K5/(4WN_C
MECU5[#*$]# 1LOUN!S8<L"][6BY/S""N5TE6V+^/6_1/9&.M-T!6"8C+5@$&
MA?D'N%//N8$MAUP2/_AM\3N9L7 #]5;J5!5*L,M34)V"#%DJ-3=P5B*S-06_
MN2",AFLX"V4;7)'5C?W"GE3$1=X-&TZQ* 05+JYH9.5G;\E"EA9EE0!L6#"2
MHX,!;MSOF22CUW!-Q8J=W$%5"#W^.1MA1,4:$)RU!HQ@GE8V1Y]!P:RMKZ14
ME,\X+GBR"MVC<YT](S]0^T9-8K8$(>^J"0:J]L?.?</(-#OJ+:2!@V-VN8:C
M.E.V SQ?2FG>&_;TF!_^>_\!4$L#!!0    (  <X/5J?H!OPL0(  .(,   -
M    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58
M=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C
M<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+
M#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\
M0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9
M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M/UY_ 5!+ 0(4 Q0    (  <X/5H'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ !S@]6H?@.!#N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ !S@]6IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  '.#U:6WB+:DH$   ($   &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ !S@]6I^@&_"Q @  X@P   T              ( !C0P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  '.#U:EXJ[',     3 @  "P
M    @ %I#P  7W)E;',O+G)E;'-02P$"% ,4    "  '.#U:JL0B%C,!   B
M @  #P              @ %2$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ !S@]6B0>FZ*M    ^ $  !H              ( !LA$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ !S@]6F60>9(9 0  SP,
M !,              ( !EQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  X1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="f8k_012925.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://globenewswire.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="f8k_012925.htm">f8k_012925.htm</File>
    <File>gnw-20190101.xsd</File>
    <File>gnw-20190101_def.xml</File>
    <File>gnw-20190101_lab.xml</File>
    <File>gnw-20190101_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "f8k_012925.htm": {
   "nsprefix": "gnw",
   "nsuri": "http://globenewswire.com/20190101",
   "dts": {
    "inline": {
     "local": [
      "f8k_012925.htm"
     ]
    },
    "schema": {
     "local": [
      "gnw-20190101.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "gnw-20190101_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "gnw-20190101_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gnw-20190101_pre.xml"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 21
   },
   "report": {
    "R1": {
     "role": "http://globenewswire.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Form8K",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f8k_012925.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Form8K",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f8k_012925.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://globenewswire.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001171843-25-000493-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-25-000493-xbrl.zip
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MH1?*P;TWV#NN\\D#_-E1:6G=);OZU6VR+R:&JL$E=3$PZXEHS?]X[#/,:1H
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M4.6/33<'4T#L **,93!U@%C G $@1%@C/M3",UY0$Q/NTGG\T''\*6"13M_
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M/!1VH0]#&7#H&(+S1FXA/#0$VP&)'- 23&%Z-!F$#)(Y3E$ F"P*\S'*2^C
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M4Z<^#+)9Q\!8Z'Y=SKH[]3!>M*U.4=M:HW7SG$Y*4X%<CN],#[*6$#[SJXD
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M"QU8R3^6G/<6X'6L.OS<RWR^,TU-]CFZ$9\/@K>40K//P^[M229SZ%N?CI_
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M5Z&KO0]$AC@S$*CMP0\*U?3OJ0M:X#[OMN*&J"L:7:]":^+N(M@ &EW, ]<
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M/$4&<L8S#QN^H*X9FCK/W[F %VDNZ0P*&HQ,R100)>%2C0QL$RD:.6KLP76
MQ[$TQ= !!";;$RLQ45/5$?*G:($&QZ:-+@H)UPE&8R?P<]:W7BF1-'F*2KR?
M927>]6J'1$>0B2J^A+M$\Z5M!8EHC]JZ&BR4]=UL ]1N=TU^6 -$J4T!$D=F
MW/]T13V4Y5L+-T&+IO*^Z7U06=O5S=AVJJ.SY.2]D.HZ&HMC!-B4.T7L0.
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M-$2&L=?:C-KMQ9M!C;IV*":^3X)F"* !]A?Z$2B+)T@$+N(XHG,D-\F@\RC
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M]&JI6#Q3J%1Y=%51^[6J.SS8U?XIB<9"--V=[6OVR*3^&*(11:*H=&ET7/;
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MQ^?A50/-3J: TM4#G[N3,^N5QAJJTC]<'>):C&Y]G:>KJ+VZ#=K>P-F_K%-
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M%Z!V;W2=6^BC<H,9?.IRW:Q#O2LMM%K?EL4 J;:NJO;PIR8'F%H[N4<0JNS
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M/0;'\Y@.JB?59CF;PI3ZA2K[6.D#AF9]QZQ0G=-N]FJ=\YEI\) VXLP.)@^
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MDWDR3^;)/)D'8OZ$B6AE\>!DNM%/5<Q.O]66]63[>Q+S*[6/153P(M\3.0J
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M7D#P$S"#X?K])F/"!S^A![0NTXX>BX_.06<T!F7(.<H_J<WGGU9W*:K]W-=
MDB3M%JG4.GG\G#%F3*+\P;B;I9\Y'U::3.)97%U[*+J8.\IMI<2\,(ID>;:;
MCUECKGAZST:O.71?K/6:JS]N])KYCS#$J_7-Q4=;Z6R:Z>RVTP'0T*[?CVXX
M<;22@J[5'?3^^4DP;W0*J!%,Z)\>^(P^3Y/B(5^A"(V38&E0^B$-8(@#_'24
MM+GSQNI=S^ 8M:.G.YTW5C9.%VDXD?E^FI<S,_CR=W\[$$CC1 SDX$8 U8TK
M6>^[]6:Q_)X5JQ.S198^QGR!??O%N%CF%8O\2R-=,,X'G]P;T:2('^,B9@>A
MJW!=Y(<UK &.AF.V;INV'I3C"4&_%F[XD27L+I[$T:R,\'+Z8'E1'5BS2;&2
M3F!_3:HJ(.,NS8R<3999&?;_*?\NFDS2Y;/. C\R1_HMN%Z-F0M'PS%;]YP:
MB53WZ?^W958&>\YR?M&UX&RL6?'%-!:SJ(QS7JK,_KV,%Y6Z"/^I_&#*+R/F
MET65! C2^+^PG1I*2=(=\4N<'E'N[X,)YWQ_-XSZ+)TP-LV-NZS\S31^+.>
MN%AFJ\_@=IG'"<OY1\%C/JUNBL7A/A3\"312J9ZXM>/77X+H>+-/=_>*_T@'
MINF23U6K'KA2>U K^M+WZG!<2Z;Z7@[@>^SGJ-JF-SK&(*=I7(EH!M@#!-XB
M\!;L W0";Q&.1O_BEX832RLIZ(8'WMI0OVV#MIYG\H-#T7DG"+D%K+&$W"+D
M%L[%*YGOK7E";J$> 527:&2][]8)N;7G9-SQD%(#8K9NFVZ@A:NK6=@3?(M_
M$&,M6"*R_M4-7:@E#Q&$ZP1(D3<^F)P(PB79W_YA56?=$*[K21G5><SO!G<Q
M6Z:1E LC3MO!UT81_V<9%Y] Z?0Z/Q[%N#KK-3P4@.1.2,5FK_=J1*I#Z?FP
M7U_?JA"8\>0>= A[<TSKZ-!IAS,.Y_V=CKP[JFVG\ (><2QQR'K?K=>PHL]<
M.NPQ,GYATS@R;A*^*ZH.A-=70=MB:$;]U\OJ\9_2^7R9E(W@VZ[\?9H5#]=S
M+FL3_:,H_WKQ$&7SJTDZ__[5\H>M6R:.4JVUY";A:]DT,SZPV<K>4[,:M^KF
MPS\^G?#V:^.WUS]7AX#S191\X2?CQ4/,5\Y)NDPFK#HAX3\_1O&L@M1&Q<JQ
M#T6Q^/;5J_GLDBVO[F?I+4O8Y_QSV53^NE<?6)XNLPE[]3K]G,S2:/KJ-@BF
MMC.^NQQ-K?#2LYE]>7LW&ETZH<5&=W?.U+&G5</X?[Y?&%4KOW]UFTZ_E/][
M*.:S'_X?4$L#!!0    (  <X/5H<6W<4\@T  #<\   .    9CAK7S Q,CDR
M-2YH=&W5&VESXCCV^_X*+5,]G=2$PT .2,(60\@,V[D6Z#GVRY2P!6C;V%Y)
M)K"_?M^3;&/ 7&DZ4Y.JZ8FMYW?K75)N_C&;N&3*A.2^=_O1*I0^$N;9OL.]
MT>W'9J_5Z7S\1^-O-V,%8 #JR=O<6*F@7BR^OKX67BL%7XR*5JU6*\X0)F>
MZK-,N'*I9!5_>WSHV6,VH7GN244]FR4?N=S[LAD_KB:@ ^'R)5!\$Q.I%-=0
MPZJS^" -?%$TBTN@*A/TW("J&)1+OUJV+K?Q82"2#V:;8"WD&21DO_W8?5B
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MU=U,!&^DZLXB_ITB_M&BFKB-_P-02P,$%     @ !S@]6H4E5ZNP @  U0L
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M(?D6G!"]KD2;B0Y8*W,(A. ^R#<O.=6]T'JJ0TA%N86F7*ZIH*4NF:*32&:
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M8B]X6 U;(6DIPT/%9J\/F#(&B2 ?)]85KO*&AO55,JW<W2O %EO'5X ;A4%
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M):BHQ?;]Y<U-M^*3V*PVB1\KG!&QY;]02P,$%     @ !S@]6FS!0-7W!@
M]E8  !0   !G;G<M,C Q.3 Q,#%?<')E+GAM;,V<T7+B-A2&[SO3=V#H-2%
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M+--AW XY%#E*S5EK$Q7[OY0H,/0#,10Y2AE:8[%AX,-<J4HPP5[%KX8B1RE
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MVO(;^\N^C-4L^1]02P$"% ,4    "  '.#U:X6>]: J'  ";_0@ "P
M        @ $     97AH7SDY,2YH=&U02P$"% ,4    "  '.#U:'%MW%/(-
M   W/   #@              @ $SAP  9CAK7S Q,CDR-2YH=&U02P$"% ,4
M    "  '.#U:A257J[ "  #5"P  $               @ %1E0  9VYW+3(P
M,3DP,3 Q+GAS9%!+ 0(4 Q0    (  <X/5JO[VJ!40@  (=D   4
M      "  2^8  !G;G<M,C Q.3 Q,#%?9&5F+GAM;%!+ 0(4 Q0    (  <X
M/5IG4='PE@H  )B%   4              "  ;*@  !G;G<M,C Q.3 Q,#%?
M;&%B+GAM;%!+ 0(4 Q0    (  <X/5ILP4#5]P8  /96   4
M  "  7JK  !G;G<M,C Q.3 Q,#%?<')E+GAM;%!+!08     !@ & 'D!  "C
%L@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>f8k_012925_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gnw-20190101.xsd" xlink:type="simple"/>
    <context id="Form8K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2025-01-29</startDate>
            <endDate>2025-01-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="Form8K" id="ixv-139">0000818686</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="Form8K" id="ixv-140">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="Form8K" id="ixv-160">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="Form8K" id="ixv-161">2025-01-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="Form8K" id="ixv-162">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="Form8K" id="ixv-163">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="Form8K" id="ixv-164">001-16174</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="Form8K" id="ixv-165">124 Dvora Hanevi&#x2019;a Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="Form8K" id="ixv-166">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="Form8K" id="ixv-167">6944020</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="Form8K" id="ixv-168">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="Form8K" id="ixv-169">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="Form8K" id="ixv-170">3-914-8213</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="Form8K" id="ixv-171">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="Form8K" id="ixv-172">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="Form8K" id="ixv-173">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="Form8K" id="ixv-174">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="Form8K" id="ixv-175">American Depositary Shares, each representing one Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="Form8K" id="ixv-176">TEVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="Form8K" id="ixv-177">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="Form8K" id="ixv-178">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
